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Abstract
Purpose To develop a European White Paper document on oropharyngeal dysphagia (OD) in head and neck cancer (HNC). 
There are wide variations in the management of OD associated with HNC across Europe.
Methods Experts in the management of specific aspects of OD in HNC across Europe were delegated by their professional 
medical and multidisciplinary societies to contribute to this document. Evidence is based on systematic reviews, consensus-
based position statements, and expert opinion.
Results Twenty-four sections on HNC-specific OD topics.
Conclusion This European White Paper summarizes current best practice on management of OD in HNC, providing recom-
mendations to support patients and health professionals. The body of literature and its level of evidence on diagnostics and 
treatment for OD in HNC remain poor. This is in the context of an expected increase in the prevalence of OD due to HNC 
in the near future. Contributing factors to increased prevalence include aging of our European population (including HNC 
patients) and an increase in human papillomavirus (HPV) related cancer, despite the introduction of HPV vaccination in 
various countries. We recommend timely implementation of OD screening in HNC patients while emphasizing the need for 
robust scientific research on the treatment of OD in HNC. Meanwhile, its management remains a challenge for European 
professional associations and policymakers.
Keywords Head and neck cancer · Dysphagia · White paper · Deglutition · Swallowing
Introduction
The state of the art and minimum standards of oropharyngeal 
dysphagia (OD) care will vary by country across Europe and 
will depend on the setting of the medical care [acute hospital, 
rehabilitation unit, community nursing home, speech-and-
language pathologist (SLP) first-line practice, etc.], the cul-
tural and religious background of the population, and the 
vision and resources available to policymakers. Given the 
need for a consensus across Europe for the treatment of OD 
in head and neck cancer (HNC), The European Society for 
Swallowing Disorders (ESSD) initiated an alliance with rel-
evant European professional medical and multidisciplinary 
societies to write a White Paper on this topic. The purpose 
of this document is to inform key stakeholders including 
health professionals from the various disciplines involved 
in the management of OD associated with HNC about the 
state of the art with regard to the different aspects of care. 
The document was written by experts from the ESSD, the 
Endorsed by the European Society for Swallowing Disorders 
(ESSD), the Confederation of European Otorhinolaryngology 
Head and Neck Surgery (CEORL-HNS), the European Head and 
Neck Society (EHNS), the Union of the European Phoniatricians 
(UEP), and the European Laryngological Society (ELS).
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Confederation of European Otorhinolaryngology Head and 
Neck Surgery (CEORL-HNS), the European Head and Neck 
Society (EHNS), the Union of the European Phoniatricians 
(UEP), and the European Laryngological Society (ELS). It 
comprises 24 sections covering all aspects of head and neck 
oncology in a broad sense including legal and ethical issues. 
A concept document comprising HNC-related topics acted 
as a foundation for the mandated contributors to add topics 
or ideas from their professional perspective. Wherever possi-
ble, a section was supported by a systematic literature review 
and we aimed to provide an up-to-date overview of what 
we believe should be essential core knowledge for health 
professionals and what should be the minimum standard of 
care for OD in the HNC setting.
Development of head and neck cancer
Etiology, epidemiology, and survival of head 
and neck cancer
HNC is one of the most common malignancies in the world, 
with high mortality rates. HNC comprises epithelial tumors 
of the nasal cavity and paranasal sinuses, nasopharynx, 
hypopharynx, larynx, oropharynx, oral cavity, lip, and 
malignant tumors of the salivary glands. More than 90% 
of these cancers are squamous cell carcinomas. The inci-
dence rates of each cancer type vary according to geographic 
region, age, gender, and various risk factors. Globally, HNC 
affected approximately 686,328 individuals in 2012 [1]. 
The majority of these cancers are located in the oral cavity 
including the lip and, in the larynx, followed by the pharynx 
[1]. It is estimated that approximately 151,000 new patients 
will be affected by HNC in Europe in 2020 [2]. Tobacco and 
alcohol have long been considered as the main causes of 
HNC. It has been reported that 72% of HNCs are related to 
tobacco smoking and/or alcohol drinking. Although tobacco 
and alcohol are considered independent risk factors, within 
this 72% 4% are attributed to alcohol alone, 33% to tobacco, 
and 35% to the combined use of alcohol and tobacco [3]. 
HNC is seen more often in men (three to five times higher) 
than in women, but this gender-related prevalence differs by 
tumor site. Geographical variation along with the differences 
in prevalence between men and women have been attributed 
to the differences in exposure to risk factors between the 
two sexes [4]. However, the male to female HNC ratio has 
been declining over time probably due to the growing num-
ber of female smokers. On the other hand, the incidence of 
smoking-related cancers such as cancers of the oral cavity, 
larynx, and other subsites is decreasing in North America 
and Western Europe, probably as a result of the reduced 
use of tobacco products [5]. There is also an age-related 
difference in HNC incidence. The highest HNC incidence 
has been observed in patients aged 65 years and older. How-
ever, the incidence of oropharyngeal and nasopharyngeal 
cancer is highest between the age of 25 and 64 years [4]. 
This is associated with viral carcinogenesis in this age group 
[4]. For example, the Epstein-Barr virus (EBV) has been 
associated with nasopharyngeal carcinoma [6] and in recent 
decades human papillomavirus (HPV), usually HPV type 
16 and 18, has attracted attention as a significant risk fac-
tor in the development of oropharyngeal cancer [6]. Sexual 
behavior is a well-recognized risk factor in the development 
of HPV-related HNC, in particular the lifetime number of 
sexual and oral sex partners [6]. Approximately one-third 
of all oropharyngeal cancers are HPV positive. The highest 
HPV prevalence is seen in tumors of the tonsil and base of 
the tongue. In this younger patient population tumors usu-
ally present as a small primary lesion with large metastatic 
lymph nodes. According to Wagner and colleagues, the 
prognosis of HPV-related HNC is better than HNC evoked 
by abuse of tobacco and alcohol [7]. The 5-year relative sur-
vival of oropharyngeal cancer increased from 37% in 1999 
to 44% in 2007 [4]. The current (2019) five-year overall 
survival rate of HNC is approximately 40–50% [4]. None-
theless, variations in survival statistics vary across different 
parts of Europe. Mortality rates are higher in Eastern Europe 
while Northern Europe has the highest 5-year survival rate 
[4]. About one-third of the HNCs present during the early 
stages and cure rates for these patients can reach up to 80%. 
In contrast, two-thirds of the patients are diagnosed in an 
advanced stage of the disease in which the survival rates 
are lower than 40%. Across Europe, the epidemiology of 
HNC reveals variations in tumor site, geography, age, gen-
der, and survival rates. These differences may be attributed 
to different cultural habits regarding risk factors for devel-
oping HNC. Finally, syndromic and familial forms of HNC 
have been described [8-11]. Patients with syndromes such 
as xeroderma pigmentosum, Fanconi’s anemia, dyskerato-
sis congenita, Bloom’s syndrome, Lynch-II syndrome, P16 
germline mutations, and ataxia-telangiectasia have a high 
risk of developing oral squamous cell carcinoma at younger 
ages and in the absence of carcinogen exposure [8–11]. 
HNC treatment modalities and the organization and deliv-
ery of care in multidisciplinary team (MDT) set-up are also 
having an effect on treatment outcome and survival rates 
as described in "Oncological treatment and its evolution" 
section.
Vulnerable head and neck cancer population—
socioeconomic disparity
As stated above, alcohol is a risk factor for developing HNC 
and alcohol abuse is an independent predictor of survival 
in HNC [12]. In a prospective study of 649 HNC patients, 
alcoholism and history of alcohol-related systemic health 
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problems such as liver disease or pancreatitis were associ-
ated with increased mortality risk, whereas abstinence was 
associated with decreased risk of death [13]. Moreover, opi-
oid naïve patients with a history of alcohol abuse had an 
increased risk for prolonged opioid use under radiotherapy 
(RT) [14]. Thus, it is essential to assess HNC patients’ his-
tory of alcohol consumption. As indicated earlier, tobacco 
is an important known risk factor for developing primary 
and relapsing HNC ("Etiology, epidemiology, and survival 
of head and neck cancer" section), patients need counseling 
and help to quit smoking. Some HNC units have established 
smoking cessation programs and support and self-help pro-
grams are available on the internet on several open access 
webpages. In 2014 the European Head and Neck Cancer 
Society published the Make Sense Campaign, which pro-
vides recommendations for best practices in the manage-
ment of psychological needs of HNC patients [15]. Emotions 
and reactions can vary during the cancer patient’s ‘journey’, 
and health professionals should be aware of these to provide 
adequate psychological support (see "Psychosocial impact" 
section). Optimal timing for suggestions/recommendations 
to attend tobacco and/or alcohol withdrawal programs is dur-
ing the posttreatment period [15]. However, patients are usu-
ally instructed to cease alcohol and/or tobacco consumption 
before HNC treatment commences.
The effects of low education, poverty, and social disad-
vantage are important considerations for the prognosis of 
HNC patients. African Americans and patients with lower 
socioeconomic status have a worse prognosis for HNC [16]. 
Dramatic disparities by ethnicity and socioeconomic status 
are not completely explained by demographics and comor-
bidity. Earlier diagnosis of HNC and timely access to surgery 
and adjuvant therapies could improve the outcomes for these 
HNC patients [16]. Neighborhood deprivation is also associ-
ated with poorer overall survival rates and an increased risk 
of developing second primary HNC among oropharyngeal 
cancer patients. Attention should therefore be paid not only 
to the individual but also to neighborhood-related risk fac-
tors [17]. Compared with patients with other cancer types, 
patients with HNC are more typically members of a minor-
ity race/ethnicity, male, poor, publicly insured, lower level 
of education, and with lower general medical and mental 
health status [18]. Attempts to improve these patients’ situ-
ation include amongst other initiatives, establishing special 
centers for homeless cancer patients [19]. Moreover, treat-
ment related to gender is also possible. A study by Park and 
colleagues revealed that women with locoregional advanced 
HNC may be undertreated, and the authors supported this 
finding using statistical models to identify those at most risk 
for undertreatment [20]. In the context of oral cavity can-
cer, patients with mental health difficulties are considered 
to have a poorer prognosis when compared to those without 
mental health issues [21]. People with intellectual disability 
as well as people with dementia may have difficulties recog-
nizing and communicating discomfort and pain during the 
development of HNC. In oral cavity cancer, for example, 
this may lead to a delayed diagnosis [22]. Poverty can affect 
outcomes for HNC patients. OD rehabilitation and dietary 
supplements are expensive, and without a proper social secu-
rity system, medical care may be inaccessible to a significant 
number of HNC patients, as is the case in many European 
countries.
In developing countries, multiple factors other than pov-
erty play a role in accessing HNC treatment. It is essential 
to create training programs and fellowships for physicians, 
nurses and other health and social care professionals both 
in their own countries and abroad to improve this situa-
tion [23]. In Europe, it is important to recognize that some 
HNC patient populations are highly vulnerable. By increas-
ing equity of treatment access, supporting socioeconomic, 
racial, and gender equality and improving education and 
screening programs, we argue that we can reduce the risk 
factors for HNC, improve outcomes and lower the rate of 
cancer recurrence in this vulnerable population.
Oncological treatment and its evolution
The treatment of choice for the majority of HNC patients 
comprises surgery and/or (chemo)radiotherapy [(C)RT]. 
Conservative transoral surgical procedures can offer a solu-
tion in the event of early HNC stages (T1–T2) of the oral 
cavity, the oropharynx, the hypopharynx, and the larynx. 
The progressive development of transoral robotic surgery 
(TORS) and transoral laser (micro)surgery (TOLS) in recent 
years has ensured that these techniques are used worldwide 
now as a single modality treatment and that the surgical 
results in early-stage HNC with regard to the oncological 
outcome are satisfactory [24–26]. The benefits of TORS and 
TOLS for early-stage tumors include a less invasive surgical 
technique, which means that the period of hospital stay is 
shorter and the risk of loss of function is considerably lower. 
It is recommended that these techniques should be carried 
out in well-selected centers by experienced surgeons [27]. 
In the case of more advanced tumors, the need for more 
‘aggressive’ procedures such as open neck surgery is rec-
ognized, often leading to severe upper aerodigestive tract 
and aesthetic function loss depending on the tumor subsite 
and the tumor stage. Although the improvement of recon-
structive surgical techniques, such as the use of microvas-
cular free flaps for cancers of the oral cavity, oropharynx, 
hypopharynx, and sometimes larynx, or the insertion of a 
voice prosthesis after total laryngectomy (TLE) has led to 
substantial progress in functional and aesthetic results, these 
surgical procedures often result in speech and swallowing 
impairment, which should be discussed with the patient 
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prior to surgery [28]. Surgical treatment of advanced-stage 
HNC is usually followed by postoperative (C)RT. It remains 
a matter of debate as to whether postoperative RT or CRT 
nullifies the beneficial functional outcome of reconstructive 
surgery. There are, however, clear indications that RT dose-
reduction on the pharyngeal constrictor muscles may lead 
to a significant reduction in immediate and late swallowing 
morbidity [29]. Recent retrospective comparisons between 
transoral surgery and RT for oropharyngeal squamous cell 
carcinoma (OPSCC) confirm that the oncological results are 
similar, with surgical approaches leading to better patient-
reported outcomes on functional results, at least in cases not 
requiring postoperative RT [30–32].
A meta-analysis performed in 2015 suggests that TORS 
and TOLS are equivalently efficacious as RT for the treat-
ment of early OPSCC in terms of oncological outcome [30]. 
In more advanced-stage OPSCC RT plays a pivotal role and 
in an attempt to optimize oncological results, chemotherapy 
(CT) or cetuximab must be administered concomitant to RT 
[33]. In the early stages of disease (T1–T2 N0) the 5-year 
overall survival following conventional RT or TORS/TOLS 
as single modality treatment varies between 70 and 80% 
[34]. In advanced tumor stages, due to local (T3–T4) or 
regional extension (N1-3) the 5-year overall survival rates 
vary between 20 and 50%. Malignant salivary gland tumors 
of any histopathology (T1–T4a) are treated with surgery 
when possible. Postoperative RT is indicated for advanced-
stage disease (T3–T4a), intermediate or high-grade tumors, 
close or irradical margins, lymph node metastases, bone 
invasion, perineural and vascular invasion, etc. [35]. Nasal 
and paranasal sinus carcinomas are usually treated with 
surgery followed by RT [36]. Due to the rarity and histo-
pathological diversity of malignant paranasal tumors, there 
is no consensus on the therapeutic approach for these can-
cers [37].
HPV-related OPSCC plays a distinct role in HNC and 
has been recently recognized as a separate entity besides 
HPV-negative OPSCC resulting in HPV-specific staging 
concepts introduced in 2018 [7, 38]. This adjustment in 
staging was necessary because patients with HPV-associ-
ated OPSCC have a noticeably better prognosis than HPV-
negative OPSCC [7, 39]. However, to date the HPV-status 
has not resulted in a de-escalation of treatment intensity. 
The 5-year overall survival rates for HPV-related OPSCC 
vary between 70% and above 80%, depending on disease 
stage [40]. Trials using cetuximab instead of cisplatin as de-
escalation strategy for HPV-positive OPSCC showed infe-
rior 2-year overall survival rates for cetuximab compared 
to cisplatin [7, 38]. In addition to the aforementioned treat-
ment modalities, it is important to emphasize the need for a 
multidisciplinary setting of HNC care. A well-functioning, 
experienced MDT is essential for optimal planning, man-
agement, and delivery of care for HNC patients. The MDT 
typically comprises otolaryngologists/phoniatricians, plastic 
and reconstructive surgeons, maxillofacial surgeons, dental 
oncologists, radiation and medical oncologists, radiologists, 
SLPs, dietitians, physiotherapists, occupational therapists, 
and HNC nurse coordinator/clinical nurse specialists [41]. 
MDTs seek input from other disciplines including dental/
maxillofacial prosthodontics/facial prosthetics, social work, 
pathology, physiotherapy, occupational therapy, psychol-
ogy/psychiatry, palliative care, and counseling. Cancer care 
guidelines advocate that HNC services should be provided 
by the MDT housed in an established, patient-centered head-
and-neck oncology center with a dedicated team of health 
professionals [42]. Protocols should consider the perspec-
tives of MDT members for different tumor types and those 
in different professions [43]. Expertise in HNC is important 
with recommended clinical criteria and minimum patient 
volumes ensuring high standard care amongst different areas 
of expertise [44, 45]. A MDT approach results in improved 
patient outcomes and better survival rates [46–49], with 
improved care coordination, reduced time to treatment, and 
adherence to clinical guidelines [50]. It is recognized that 
delivery of MDT services through a coordinated head and 
neck clinical pathway (HNCP) maximizes results, increases 
efficiency in care delivery, reduces costs, shortens the length 
of hospital stay, and improves overall patient outcomes 
[51–55]. Coordination of a HNC MDT may be challeng-
ing [54], yet, despite its complexity, we argue that positive 
clinical, patient, and service outcomes can best be achieved 
through the implementation of a well-designed HNCP and 
MDT approach.
Oropharyngeal dysphagia in head and neck 
cancer
Pathophysiology and mechanisms of oropharyngeal 
dysphagia
Many HNC patients experience some degree of OD [56, 
57]. The nature and degree of OD depend on the site and 
size of the primary tumor, with most severe complaints 
reported by patients with advanced oropharyngeal and 
hypopharyngeal lesions and those with cervical esopha-
geal cancers [58]. Swallowing is a complex sensory-motor 
function. All stages of the physiologic swallowing process 
including motility, sensitivity, and biomechanical events 
may be altered in HNC patients. The oral preparatory phase 
(adequate lip closure and buccal tone for bolus containment, 
mastication and bolus formation), the oral phase (voluntary 
tongue strength, competent tongue function to move the 
bolus within the mouth and posteriorly), the pharyngeal 
phase (very rapid series of reflexive actions where the tim-
ing of biomechanical events is crucial), laryngeal elevation 
581European Archives of Oto-Rhino-Laryngology (2021) 278:577–616 
1 3
and anterior hyolaryngeal excursion with upper esophageal 
sphincter (UES) relaxation and bolus weight to open the 
UES, and the esophageal phase (completely involuntary) 
may be compromised. Changes in the lingual driving force, 
the pharyngeal clearing forces, the hypopharyngeal suc-
tion pump, and laryngeal competence may affect pharyn-
geal swallowing [59]. Pre-existing swallowing problems 
are usually worsened by the oncological treatment. Surgery 
may comprise resection of important swallowing structures, 
involving muscles and nerves leading to sensory-motor dys-
function and incoordination of swallowing, whereas (C)RT 
may lead to other pathophysiological changes. Damage to 
the oral cavity may lead to predictable but complex swallow-
ing problems, such as difficulty with mastication, controlling 
food or liquid in the mouth, and initiating the pharyngeal 
swallow. Resections of up to one-third of the mobile tongue 
result in transient swallowing problems, but more severe 
problems occur when the tongue is tethered to the floor-
of-mouth by the method of surgical closure, or when flap 
reconstruction leads to a non-innervated mass, modifying 
the spatial pattern and stereognosis of the oral cavity, or if 
sacrifice of the hypoglossal nerve is necessary [60]. Exci-
sion of the oropharynx causes more severe OD since the 
tongue base plays a critical role in initiating swallowing, 
propelling the bolus through the pharynx in combination 
with efficient pharyngeal peristalsis [61]. Any HNC treat-
ment procedure that impacts oral containment of the bolus 
can result in premature loss of the bolus into the pharynx and 
aspiration risk [62]. This can subsequently result in delayed 
respiratory tract protection with aspiration before the swal-
low, reduced pressure generation, postswallow pharyngeal 
pooling, or reduced laryngeal elevation causing residue and 
postswallow aspiration especially in the presence of sensory 
deficits [63]. Combined resections of the soft palate and ton-
sillar pillars may affect pharyngeal bolus transport causing 
nasopharyngeal reflux and pharyngeal residue. Partial laryn-
gectomy may be responsible for delayed and limited eleva-
tion of the larynx [64]. When (C)RT is employed frequent 
acute side effects include mucositis, edema, OD, and xeros-
tomia [65, 66]. Posttreatment side effects decline within a 
few months in the majority of the patients. Late morbidity 
(> 6 months) is usually related to (C)RT and local damage 
caused by the tumor. Various degrees of fibrosis occur in the 
oropharyngeal muscles involved in the first two phases of 
swallowing. Sensory nerve function is often affected follow-
ing HNC treatment thus modifying bolus propulsion, bolus 
localization, and oral stereognosis. Fibrosis of the pharyn-
geal constrictor muscles can lead to swallowing difficulties, 
symptomatic or silent aspiration and thus, often affects eat-
ing with considerable risks leading to feeding tube depend-
ency [67–69]. As the salivary glands are often involved in 
the RT fields for oropharyngeal cancer, various degrees of 
xerostomia further complicate swallowing [70]. Being able 
to swallow following HNC treatment is one of the top func-
tional priorities in patients and a driver for health-related 
quality of life (HRQOL) [71]. Modern RT techniques such 
as intensity-modulated radiotherapy (IMRT) allow for par-
tial sparing of the parotid glands and the oral cavity and have 
the potential to lower the dose to the pharyngeal constrictors 
[72, 73]. The aim after oncological treatment is to return 
to oral feeding often with the help of an allied health pro-
fessional and early speech therapy intervention to optimize 
swallowing outcomes [74]. Within the HNC population, the 
group of TLE patients represents a special sub-population. 
As the risk of choking is ameliorated in the absence of a 
larynx, these patients often receive less attention both in 
the clinic and in scientific OD research. In  "Oropharyngeal 
dysphagia following total laryngectomy" section the diag-
nosis and treatment of OD after a TLE is further described.
Tracheostomy and oropharyngeal dysphagia 
in head and neck cancer
The need for a tracheostomy can be caused by the HNC itself 
or by the oncological treatment modalities such as (C)RT 
and surgery or combinations thereof. The upper respiratory 
tract can be compromised due to tumor obstruction, tumor 
destruction or paralysis of cranial nerves. HNC treatment 
can lead to lymphedema, fibrosis, and adhesion or synechia 
formation of the laryngeal mucosal membrane, which can 
compromise ventilation. Treatment often causes changes to 
saliva viscosity, which impairs the spontaneous handling 
of secretions in the throat leading to hypopharyngeal resi-
due and salivary spilling into the larynx with subsequent 
aspiration.
Tracheostomy changes the anatomy and physiology of 
breathing, altering the timing and interaction of respiration and 
swallowing. This altered airway mechanism compromises the 
cough reflex and the ability to clear the airways due to changes 
in airflow and to the sensitivity of the larynx, which may 
affect the patients’ handling of secretions [75, 76]. Although 
a tracheotomy is usually performed to ensure breathing and 
ventilation, it is not without side effects. Besides the risk of 
bleeding and infection, which comprises both pneumonia or 
wound infection, other adverse events have been reported. 
These include secondary sinusitis, pneumothorax, subcutane-
ous emphysema, and persistent damage of the tracheal carti-
lage [77]. The one-year overall survival after tracheotomy in 
a mixed population in need for airway assistance (both neu-
rological intensive care unit and HNC population) was 50% 
[78]. Assessment of OD in the presence of a tracheostomy tube 
remains subject of debate. The Modified Evan’s Blue Dye Test 
(MEBDT) is considered as a screening tool for aspiration in 
tracheotomized patients. However, the literature in this area 
is divergent and the MEBDT is not considered diagnostically 
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accurate in the decision-making on OD management and/or 
the weaning procedure in HNC patients [79, 80].
Eating with a tracheostomy tube in situ has been evaluated 
in function of tracheostomy tube status (occlusion versus open 
tube). Leder and colleagues did not find significant differences 
in aspiration rate between these tube status conditions [81, 82]. 
Cuffed tracheostomy tubes are used to seal the airway when 
there is a need for positive pressure ventilation—or to prevent 
food or saliva entering the lower respiratory tract. Tracheos-
tomy tubes or cannulas with a cuff might help in decreasing 
aspiration of secretions in the lower respiratory tract and can 
be used for tracheobronchial suction cleaning in case of severe 
aspiration. The evidence of whether a cuffed tube prevents 
further bolus aspiration into the lower respiratory tract while 
eating and drinking is still inconclusive [83]. Unfortunately, 
the clinical perception still persists that tracheotomy and place-
ment of a tracheostomy tube increases the incidence of aspi-
ration and decannulation causes improvement of swallowing 
function.
According to some studies, the tracheal tube cuff status 
(inflated versus deflated) might affect swallowing physiol-
ogy too [84–86]. In a retrospective study of tracheotomized 
patients with mixed etiologies, subgroup analysis of the 102 
HNC patients showed that postswallow residue and silent 
aspiration were the most frequent signs of swallowing impair-
ment [84]. The authors found reduced laryngeal elevation and 
reduced laryngeal and pharyngeal sensitivity during cuff infla-
tion. However, in a further study with tracheotomized patients, 
the authors did not find tethering of the larynx during vide-
ofluoroscopic swallow study (VFSS) using tubes with and 
without cuff [86]. This finding was confirmed later by Leder 
and colleagues where pre- and post-tracheotomy swallowing 
evaluation failed to show a direct causal relationship between 
tracheostomy and aspiration status [87]. In conclusion, the 
presence of OD is usually caused by the underlying disease 
or condition rather than by the tracheostomy itself. It is sug-
gested here that this is also the case for HNC patients who 
have undergone extensive HNC treatment for advanced HNC 
stages irreversibly affecting their upper aerodigestive tract. 
Most experts agree that in the context of best clinical practice 
a MDT should assess secretion handling, swallowing, and the 
weaning procedure in tracheotomized HNC patients using 
fiberoptic endoscopic evaluation of swallowing (FEES) and/
or VFSS (see "Videofluoroscopic swallow study " and "Fiber-
optic endoscopic evaluation of swallowing" sections) [88].
Screening and clinical assessment 
of oropharyngeal dysphagia in head 
and neck cancer
The first step in the management of patients at risk for 
OD is screening. The purpose of screening is to identify 
patients at risk for aspiration or swallowing problems. 
Any HNC patient at risk of OD should be screened. HNC 
patients at risk of OD are usually screened on their initial 
pretreatment appointment before the onset of oncological 
treatment. Screening results in a pass or a fail; patients 
are deemed to be either at risk (screen failed) or are not 
at risk (screen passed). Patients who fail screening must 
be referred for further assessment to evaluate the swallow 
physiology and functioning and, if possible, determine 
the cause of swallowing problems [89]. Depending on 
the acuteness and stability of a patient’s health, screening 
must be repeated to confirm or adjust previous screening 
outcomes. Patients who passed earlier screening, but are 
subject to changing health conditions due to for exam-
ple aging or the effects of oncological treatments may be 
at risk of developing OD over time. Screening measures 
must be valid, reliable, and feasible to administer. Recent 
diagnostic reviews provide overviews of existing screening 
measures and their diagnostic performance (e.g., sensitiv-
ity, specificity, positive predictive value, negative predic-
tive value, and likelihood ratios). Several reviews recom-
mend water swallowing tests using different endpoints 
(e.g., choking, coughing) [90–95] to determine whether 
patients passed or failed screening. Even though these 
reviews did not specifically target HNC patients, the use 
of a water swallowing test seems to be the most appropri-
ate choice in the absence of diagnostic reviews involving 
HNC patients only.
Given that OD is a multi-faceted phenomenon [96, 
97], different dimensions of swallowing do not necessar-
ily correlate. As such, a multidimensional approach to 
the assessment of OD is needed, including medical and 
patient history taking; conducting instrumental assess-
ments including FEES or VFSS, and administering clini-
cal assessments and patient self-reports [89]. Medical and 
patient history information will provide information on 
factors associated with OD, including (but not limited 
to): respiratory impairment and use of medication; the 
presentation (or possibly representation) of pneumonia 
and sudden unexplained weight loss, etc. Clinical assess-
ment comprises a broad range of assessments, including 
the functional assessment of cognition and communica-
tion abilities; the evaluation of the oral, laryngeal, and 
pharyngeal functioning in terms of physiology, anatomy, 
and neurology, with a specific focus on cranial nerve func-
tion; oral intake; and oral health. The dietary intake and 
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nutritional status can be reviewed by assessments such as 
the Functional Oral Intake Scale (FOIS) [98] or the Mini 
Nutritional Assessment (MNA) [99]. Mealtime observa-
tions and trial swallows, using different bolus consisten-
cies and volumes, possibly in combination with postural 
adjustments and swallowing maneuvers, are conducted to 
evaluate safety and efficacy of swallowing and options for 
OD treatment [89, 100]. However, instrumental assess-
ment is required, for example, to rule out silent aspiration 
or retrieve more detailed information about the swallow-
ing act.
Patient self-evaluation of functional health status (FHS) 
and HRQOL are conducted by means of self-administered 
questionnaires. FHS refers to the influence of a given dis-
ease or OD on particular functional aspects – for example 
– an individual’s ability to perform normal daily activi-
ties such as eating required to meet basic needs, fulfill 
usual roles, and to maintain health, and well-being [101]. 
HRQOL, conversely, is the unique personal perception of 
someone’s health, taking into account social, functional, 
and psychological aspects [102]. Many questionnaires, 
however, combine FHS and HRQOL without making a 
distinction between the two constructs. Commonly used 
HRQOL questionnaires in oral health (e.g., 5-item Oral 
Health Impact Profile or OHIP-5) [103] are not specifically 
developed for patients with HNC, with the exception of 
the oral health supplementary questionnaire module by 
the European Organization for Research and Treatment of 
Cancer Quality (EORTC QOL-OH15) [104]. It is recom-
mended that the EORTC QOL OH-15, which focuses on 
oral health, should be administered in conjunction with the 
HRQOL questionnaire EORTC QLQ-C30. This EORTC 
QLQ-C30 focuses on general quality of life (QOL) in HNC 
patients [105]. Still, very few questionnaires specifically 
target OD-related QOL in HNC patients. Examples include 
the MD Anderson Dysphagia Inventory (MDADI) [106] 
Table 1  Examples of commonly used screening and clinical assessments in head and neck cancer patients with oropharyngeal dysphagia
a No international consensus exists on which screening or assessment for dysphagia is preferred in head and neck cancer patients [97]. In addi-
tion, many screenings and assessments have unknown or poor psychometric properties or have not been validated for head and neck cancer 
patients. The presented list of screenings and assessments does not provide a complete overview, but examples of common clinical practice
b Targeting patients with head and neck cancer
Domain Screening and clinical  assessmenta Acronym References
At risk of swallowing problems Screening: water swallowing test using different endpoints, 
e.g.:
100 ml Water Swallow  Testb 100 ml WST [460]
Toronto Bedside Swallowing Screening Test TOR-BSST [461]
Volume-Viscosity Swallowing Test V-VST [462]
Cognition and Communication Mini-Cog Test [463]
Mini-Mental State Examination MMSE [464]
Nutritional status Malnutrition Universal Screening Tool MUST [465]
Mini Nutritional Assessment





Oral intake status Functional Oral Intake Scale FOIS [98]
Health-related quality of life Quality of Life Questionnaire (by the European Organization 
for Research and Treatment of Cancer Quality)b
EORTC QLQ-C30 [105]
Dysphagia-related quality of life MD Anderson Dysphagia  Inventoryb MDADI [106]
(including functional health status) Symptom scale Swallowing of the Head and Neck Cancer 
Module (by the European Organization for Research and 
Treatment of Cancer Quality)b
Symptom scale Swallowing 
of the EORTC QLQ-
H&N35
[107]
Dysphonia-related quality of life
(including functional health status)
Voice Handicap Index VHI [467]
Oral health status 5-item Oral Health Impact Profile OHIP-5 [103]
Oral Health supplementary questionnaire module (by the Euro-
pean Organization for Research and Treatment of Cancer 
Quality)2
EORTC QOL-OH15 [104]
Anatomy/cranial nerve integrity Clinical examination of the tongue, hard and soft palate, teeth, gums, oral mucosa, trigeminal (V), facial 
(VII), glossopharyngeal (IX), vagal (X), and hypoglossal (XII) cranial nerves
Oral motor skills/physiology Clinical examination of oral muscle strength, range, tone, steadiness, accuracy, and coordination
Mealtime observation including observation of drooling or sialorrhea, mastication, eating speed, cough 
or choking, oral residue, head and body positioning
Compensatory strategies/maneuvers E.g.: bolus modification, postural adjustments and/or swallow maneuvers
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and the QLQ-H&N35, which has a 4-item subscale on 
swallowing [107].
Table 1 provides examples of commonly used screening 
and clinical assessments in HNC patients with OD. How-
ever, when selecting measures, only those with robust psy-
chometric properties should be selected, otherwise patient 
data cannot be interpreted as valid and reliable and no clini-
cal inferences should be made [108, 109]. Recent psycho-
metric reviews on measures in OD have indicated their psy-
chometric status as either poor or lacking data on validity, 
reliability, and responsiveness in, for example, measures on 
FHS, HRQOL or visuoperceptual evaluation of FEES and 
VFSS [110–112]. Item Response Theory (IRT) has been 
introduced as a contemporary methodology to interrogate 
the psychometric quality of measures and should be used in 
combination with Classical Test Theory (CTT) [109, 113, 
114]. Although procedures and interpretation of CTT are 
relatively straight forward compared with IRT, CTT has 
some limitations. The CTT framework evaluates the per-
formance of the measure as a whole and is specific to the 
sample population the measure was tested with. By contrast, 
in IRT the unit of analysis is the item and results are not 
bound by the test population [114, 115]. In recent years, 
IRT has been used to evaluate and critique measures com-
monly used in OD which calls for the development of new 
measures or the refinement of existing measures [116–119]. 
Future research should focus on comprehensively evaluating 
all psychometric properties for existing measures and devel-
oping new measures validated in patients with HNC using 
contemporary standards for instrument development, such 
as COnsensus-based Standards for the selection of health 
Measurement INstruments (COSMIN) [120].
Instrumental swallowing assessment in head 
and neck cancer
Videofluoroscopic swallow study
As the findings from both feeding status of the patient 
and patient-reported outcomes may not always be associ-
ated with findings from VFSS assessment in HNC patients 
[121–123], instrumental swallow evaluation is critical to 
provide prompt OD management. VFSS is a dynamic radio-
logical imaging examination, which provides direct visuali-
zation of bolus flow and structural movement during the oral 
preparatory, oral, pharyngeal, and upper esophageal stages 
of swallowing. VFSS is employed to evaluate oropharyngeal 
swallowing and to guide interdisciplinary OD intervention. 
VFSS can capture the impact of HNC, surgical interven-
tion, and (C)RT on oropharyngeal swallowing over time. 
The esophageal phase of swallowing can also be screened 
during VFSS to determine the need for onward referral and 
more in-depth esophageal evaluation [124]. VFSS should 
be selected over FEES when oral or esophageal phase dys-
phagia is suspected based on the clinical evaluation. During 
the VFSS protocol, lateral and anterior–posterior views are 
obtained. Initially, the patient is seated in the lateral position 
and an optimum view should be obtained to evaluate oro-
pharyngeal swallow anatomy at rest to rule out any structural 
abnormalities or complications resulting from HNC or sur-
gical treatment (e.g., tracheo-esophageal fistula). Standard-
ized liquid bolus volumes impregnated with barium should 
be administered with the patient in a head neutral position. 
Method of bolus delivery can alter swallowing and patients 
should be encouraged to self-feed from a cup or spoon where 
possible to replicate real-life eating behavior. When safe, 
larger liquid bolus volumes can rule out cricopharyngeal 
and upper esophageal pathologies (e.g., posterior cricoid 
web, cricopharyngeal bar, laryngo-pharyngeal reflux) and 
can expose impaired UES opening during swallowing due to 
post-RT fibrosis of suprahyoid, pharyngeal constrictor or cri-
copharyngeal musculature [124–126]. Where safe, a range 
of bolus consistencies (thin liquids, nectar thick, pudding, 
solid) should be trialed during VFSS. Solid foods may be 
challenging for patients with impaired mastication result-
ing from trismus; weak lingual range of movement second-
ary to RT-induced fibrosis; xerostomia or altered taste. An 
anterior–posterior view should also be included during the 
VFSS protocol to evaluate the symmetry of pharyngeal or 
upper esophageal residue and to observe vocal fold adduc-
tion. Finally, an esophageal screen is critical during VFSS. 
Despite the fact that VFSS is not very sensitive to detect 
esophageal cancer and gastro-esophageal reflux disease, it 
can still contribute to a global assessment of the esophageal 
phase of swallowing and the need to refer the HNC patient 
to the gastroenterologist [127]. Of note, VFSS pulse rate 
should be considered as VFSS findings differ using a rate 
of 30 pulses per second compared to 15 pulses per second 
[128, 129].
Where aspiration or residue is observed during VFSS, 
compensatory strategies should be trialed before introduc-
ing modified diet consistencies. While the evidence base for 
compensatory strategies is very limited in the HNC popula-
tion [130], postures (e.g., chin tuck, head turn) and maneu-
vers (e.g., effortful swallow, supraglottic swallow, Mendel-
sohn maneuver) can alter swallow safety and efficiency and 
are often preferred by people with swallowing difficulties 
to diet modification [131]. As many patients with OD sec-
ondary to HNC already present with weight loss, decreased 
appetite, taste changes, and malnutrition, these strategies 
should be tested during VFSS.
In terms of VFSS interpretation, validated rating scales 
should be employed to monitor swallowing performance 
over time and to establish any response to intervention 
(see "Screening and clinical assessment of oropharyngeal 
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dysphagia in head and neck cancer" section). Swallow safety 
can be rated using the Penetration Aspiration Scale (PAS) 
[132]. This is a visuoperceptual eight-point ordinal rating 
sale, which measures the depth of airway invasion and the 
presence and efficiency of a cough response to aspiration 
[132]. Swallow efficiency is commonly rated using vali-
dated perceptual or quantitative residue scales including the 
Bolus Residue Scale [133] and the Normalised Residue Rat-
ing Scale [134]. The Dynamic Imaging Grade of Swallow-
ing Toxicity (DIGEST) is a five-point rating scale recently 
developed and validated for the HNC population, which cap-
tures both swallow safety and efficiency [135]. To provide 
safe and beneficial OD rehabilitation, clinicians must look 
beyond aspiration and residue during VFSS interpretation to 
identify the underlying pathophysiology. Tools such as the 
Modified Barium Swallow Impairment Profile (MBSImp), 
a standardized VFSS scoring system, which involves rating 
various physiologic components of swallowing [136], can 
help to identify the underlying physiological cause of OD. 
Components typically altered in HNC patients include ante-
rior and superior hyoid excursion, UES opening, initiation of 
swallowing, tongue base retraction, and pharyngeal residue 
[121]. As described in "Screening and clinical assessment 
of oropharyngeal dysphagia in head and neck cancer" sec-
tion there is still room for improvement of the psychometric 
properties of VFSS measures in patients with HNC.
Fiberoptic endoscopic evaluation of swallowing
FEES, first described by Langmore in 1988, allows the ana-
tomical assessment of the pharynx and larynx, providing 
an excellent visualization of the anatomical and physiologi-
cal changes after HNC surgery and/or (C)RT. Inspection 
of the UES is also possible but it requires frame by frame 
analysis and is easier in cases of patent UES. FEES also 
allows a comprehensive evaluation of the pharyngeal stage 
of swallowing [137, 138]. Together with the VFSS, FEES is 
the most commonly recommended method of instrumental 
swallowing assessment for HNC patients in many guide-
lines [139–141]. It is a safe procedure with a reported low 
incidence of complications in patients with OD of mixed 
etiology [142].
To perform a FEES examination both clinical skills in 
handling the endoscope and knowledge on swallowing 
anatomy, (patho)physiology, and rehabilitation are required 
[143, 144].
Currently, there is no consensus in the literature on a 
FEES protocol for HNC. However, studies on this topic 
[145–147] recommended a comprehensive evaluation of 
swallowing that includes the assessment of the anatomy of 
the upper aerodigestive tract, sensibility of the larynx, motor 
control of swallowing structures, secretion management, 
effect of bolus modification (volumes and consistencies) 
and swallowing maneuvers. The assessment of the upper 
aerodigestive tract; plays a critical role in HNC patients as 
it allows appraisal of surface mucosa as well as the struc-
tural integrity and changes in swallowing structures. Surface 
mucosa assessment is a medical act of pivotal importance 
as it may reveal diseases, such as mycosis or recurrent car-
cinoma requiring prompt diagnosis and treatment. Both 
surgical and non-surgical HNC treatment often lead to sig-
nificant structural changes, such as UES stricture formation 
or patency, pharyngeal tissue thickening (edema and/or 
fibrosis), volume changes of the tongue base and pharynx, 
etc., that require anatomic and functional assessment. Sensi-
bility of the larynx and motor control of the velopharyngeal 
sphincter, pharynx, tongue base, and larynx during non-
swallowing tasks should be carefully assessed [148–150]. 
Sensory impairments in the larynx after (C)RT are common 
and may contribute to aspiration [151]. However, further 
research is needed to determine the late effects of HNC treat-
ment, in terms of prevalence – biomechanism – etc., on the 
oropharyngeal and laryngeal sensory function.
Secretions and swallowing performance with different 
bolus volumes and consistencies are mandatory during a 
FEES examination. The presence of secretions in the lar-
ynx of HNC patients is a common finding and it can be 
associated with a high risk of aspiration [152]. There is no 
consensus on the number of swallow trials, bolus volume 
or consistencies applied during FEES. Studies reported that 
the number of swallow trials necessary to reveal aspiration 
for thin liquid is smaller in HNC patients when compared 
to neurology patients [153]. In both patient populations, the 
aspiration risk is underestimated when using a limited num-
ber (three or four) of swallow trials. At least 6 swallow trials 
with thin liquids and 4 swallow trials with thickened liquids 
should be assessed to avoid underestimation of aspiration 
probability [153]. Different bolus consistencies should be 
offered during FEES as swallowing performance changes 
according to the consistency [154]. Swallow trials of differ-
ent bolus volumes and consistencies are crucial for decision-
making on oral intake. However, to understand the swal-
lowing pathophysiology all aspects involved in swallowing 
(anatomy, sensibility, motor control, secretion management, 
and swallowing performance) should be assessed.
The effect of different interventions (diet modification, 
application of compensatory strategies, and airway protec-
tive swallow maneuvers) on swallowing function should be 
assessed during FEES as it can guide decision-making on 
oral feeding and the rehabilitation program [138].
There are several advantages of using FEES in HNC 
patients; for instance, it allows the assessment of swallow-
ing, voice, and local tumor recurrence in the same examina-
tion. Although FEES has been extensively applied in HNC 
patients [145], particularly after open partial laryngeal sur-
gery [155], standardization and validation of FEES rating 
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scales for HNC populations require further development 
(see "Screening and clinical assessment of oropharyngeal 
dysphagia in head and neck cancer" section) [111]. Given 
that HNC patients often present with anatomical and func-
tional changes in the oropharyngeal structures, as well as a 
high prevalence of comorbidity, the psychometric proper-
ties of existing FEES scales cannot simply be extrapolated 
to a HNC patient population. FEES rating scales, such as 
the PAS [132, 156] and the Yale Pharyngeal Residue Rat-
ing Scale [157], were not specifically developed for HNC 
patients. An exception is the adaptation of the PAS for 
patients who underwent partial laryngectomy [158] and the 
scale developed to evaluate swallowing residue post-TLE 
[159]. Although the level of intra- and interobserver agree-
ment of the FEES rating scales was reported to be similar in 
neurology and oncology patients [160] there is insufficient 
evidence that FEES scales developed and validated for neu-
rogenic OD are also suitable to evaluate swallowing in HNC 
patients. Further studies should analyze the psychometric 
characteristics of existing FEES scales in HNC patients or 
develop and validate FEES protocols specifically for this 
population.
FEES and VFSS are both well-established instruments to 
assess swallowing and their advantages and disadvantages 
have already been described in the literature [161, 162]. The 
main differences are that only FEES is able to assess the 
surface mucosa, saliva residue, and laryngeal sensory func-
tion; it can be performed at the bedside and repeated as often 
as needed as there is no radiation exposure. On the other 
hand, only VFSS allows oral and esophageal phase visu-
alization, including the assessment of oropharyngeal transit 
timing and UES opening. Findings of simultaneous FEES 
and VFSS examination have shown that FEES may lead to 
a more severe impression of pharyngeal residue based on a 
superior visualization of the bolus [163–165]. Studies on 
the correlation between FEES and VFSS in HNC patients 
have shown similar results regarding outcomes on pharyn-
geal residue [159, 166]. However, aspiration was perceived 
as less severe during FEES in HNC patients probably due 
to the restricted view of the larynx based on among others 
mucosal edema [166].
Manometry
In the past, high-resolution manometrie (HRM) has been 
used to investigate upper gastrointestinal, usually esoph-
ageal function. In the last decade, HRM is increasingly 
applied to evaluate the muscular function of the pharynx 
and the UES during deglutition [167]. HRM measures 
contraction of the entire pharynx and the UES segment 
using a transnasal catheter with closely spaced pres-
sure sensors. HRM can be combined with VFSS and/or 
impedance measurements and has been incorporated into 
commercially available diagnostic systems.
The pharyngeal phase of swallowing consists of a series 
of actions, which can be identified using a HRM color 
plot. Firstly, laryngeal elevation can be seen by an upward 
movement of the UES. Secondly, the pharyngeal contrac-
tile wave is registered as a peristaltic sequence of pressure 
increase over time along the entire pharynx. Thirdly, the 
UES relaxation is identified by a pressure drop overtime at 
the UES high-pressure zone with a recovery back to UES 
resting pressure baseline. Finally, the proximal esophageal 
contraction can be recognized by an increased pressure in 
the UES and the proximal striated part of the esophagus 
[168].
The UES compliance depends on both UES relaxation 
and UES opening, which are different yet closely inter-
linked. UES opening is an active neuromuscular event 
rather than a single consequence of UES relaxation and the 
diameter of the opening varies according to bolus volume 
and consistency [169–171]. It is important to recognize 
that HRM as a standalone technique allows measurement 
of UES relaxation, but is unable to measure UES opening 
in terms of the diameter.
When HRM is recorded simultaneously with intralumi-
nal impedance measurement, combined manometry imped-
ance patterns can be analyzed in an integrated fashion using 
pressure-flow analysis (PFA). PFA derives pharyngeal pres-
sure-impedance variables, which are objective metrics of 
deglutitive function and are altered in relation to impaired 
swallowing [172, 173]. Aspiration risk can be assessed 
through a swallow risk index (SRI), which is a formula com-
bining four pharyngeal pressure-impedance parameters rele-
vant to aspiration [172, 173]. In neurogenic OD as well as in 
HNC patients, the reliability and validity of the PFA-derived 
SRI and the measure of postswallow residue were evaluated 
by comparing them against VFSS as the criterion reference 
standard. Studies have shown that PFA-based measures of 
swallowing function have good interobserver reliability and 
that these measures are easily determined and are objective 
markers of clinically relevant features of OD [174, 175]. 
Nowadays, the use of HRM for assessment of pharyngeal 
and UES motor function is common in clinical practice. 
Recently, a High-Resolution Pharyngeal Manometry Inter-
national Working Group reached a consensus on methodol-
ogy, protocol, and metrics for high-resolution pharyngeal 
manometry (HRPM) with consideration of impedance as an 
adjunct modality [176]. Normative values and online analy-
sis methods are now available and a classification system 
for UES motility disorders has been developed [177]. HRM 
has significant potential in determining the pathophysiology 
of OD in HNC patients and future studies could potentially 
benefit highly from including these objective measurements.
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Complications due to oropharyngeal 
dysphagia in head and neck cancer
This section deals primarily with airway-related problems 
due to OD. Other consequences of OD are discussed in 
separate sections. The topic of positive short- and long-
term outcomes for upper aerodigestive tract function asso-
ciated with low complication rates is one of increasing 
importance [178, 179].
Both surgical and non-surgical treatment of HNC 
can result in transient or permanent OD as described in 
"Pathophysiology and mechanisms of oropharyngeal dys-
phagia" section [178]. OD puts the patient not only at risk 
for aspiration pneumonia, malnutrition, dehydration, and 
choking, which all increase morbidity but also for reduced 
QOL [180]. Incidence, diagnosis, and management of mal-
nutrition and dehydration are described in further detail 
in "Cancer cachexia in head and neck cancer" and "Treat-
ment of cancer cachexia" sections. Aspiration pneumonia 
is recognized as pneumonia secondary to the entrance of 
food particles, saliva, or gastric acid into the lower respira-
tory tract [181]. Definitions for aspiration pneumonia vary 
according to the literature. Kawai and colleagues defined 
aspiration pneumonia as the presence of wet cough, spu-
tum, and fever in addition to coarse crackles in the chest, 
elevated inflammatory serum markers and image findings 
(X-ray or computed tomography scan of the chest) [181]. 
The incidence of aspiration pneumonia within a year after 
(C)RT differs, ranging from 5.4 to 23% [182–184]. Varia-
tion in incidence may be due to a higher risk of aspiration 
pneumonia following CRT or cetuximab with concur-
rent RT than following RT as a single modality treatment 
[185]. Malnutrition with hypoalbuminemia is described 
as a predictive factor for aspiration pneumonia after (C)
RT as hypoalbuminemia negatively affects the immune 
system [185]. Further predictive factors for aspiration 
pneumonia following (C)RT are poor oral hygiene (OH), 
use of sleeping pills, coexistence of other malignancies, 
and habitual alcohol consumption [181]. Szczesniak and 
colleagues reported that approximately 52% of the patients 
who received RT and 69% who received (C)RT suffered 
from long-term OD after treatment, and aspiration pneu-
monia accounted for 19% of non-cancer-related deaths 
[186]. Therefore, clinicians should assess the risk of aspi-
ration pneumonia to identify patients for whom efforts to 
prevent aspiration pneumonia should be intensified [181]. 
Screening for aspiration with a clinical swallowing test 
for HNC [e.g. Mann Assessment of Swallowing Ability-
Cancer (MASA-C)] and subsequently verifying positive 
screening results with a FEES or VFSS assessment, should 
be performed if aspiration is suspected ("Screening and 
clinical assessment of oropharyngeal dysphagia in head 
and neck cancer", "Videofluoroscopic swallow study", 
and "Fiberoptic endoscopic evaluation of swallowing " 
sections) [187–189]. The body of literature on compara-
tive incidence and duration of aspiration following con-
ventional HNC surgery, TOLS or TORS remains limited 
at present [178]. This is the subject of ongoing clinical 
trials. Aspiration should be anticipated and avoided as far 
as possible by using airway protective swallow maneuvers 
under the guidance of specialized SLPs, general patient 
education, bolus modification ("Bolus consistency modi-
fication" section), and sometimes tracheostomy for bron-
chopulmonary suction ("Tracheostomy and oropharyngeal 
dysphagia in head and neck cancer" and "Surgical treat-
ment of oropharyngeal dysphagia in head and neck cancer" 
sections) [151, 181].
Cancer cachexia in head and neck cancer
Cancer cachexia is defined by Fearon and colleagues is “A 
multifactorial syndrome characterized by an ongoing loss 
of skeletal muscle mass (with or without loss of fat mass) 
that cannot be fully reversed by conventional nutritional 
support and leads to progressive functional impairment” p. 
490 [190]. The pathophysiology is characterized by distur-
bances in the whole body and cellular energy metabolism, 
muscle protein turnover regulation, and impaired muscle 
regeneration [190, 191]. Next to these metabolic distur-
bances patients often suffer from a reduced oral food intake 
and appetite [190, 192]. Within the HNC population, the 
incidence of cachexia varies from 6.1 to 66%, depending 
on the time in relation to treatment and cachexia is more 
pronounced in locally advanced tumors [193–195]. Multi-
ple studies have shown that cachexia is related to decreased 
therapy tolerance, higher treatment toxicity, and above 
all worse overall survival and progression-free survival 
[193–197]. OD is one of the factors leading to a reduced 
oral food intake in HNC patients [198]. Furthermore, cata-
bolic processes causing muscle atrophy [199] might not only 
affect peripheral skeletal muscles but also swallowing mus-
cles. The muscle wasting component in HNC patients’ OD 
is still underexplored, but OD due to sarcopenia (sarcopenic 
OD) in the elderly population has been reported [200–203]. 
Additionally, in cancer patients, an association has been 
found between skeletal muscle mass and severe OD [204, 
205]. Feng and colleagues showed that the cross-sectional 
area of the geniohyoid muscle, as surrogate for swallowing 
muscle volume, was significantly lower in aspirating elderly 
men compared to non-aspirators [206]. These studies sup-
port the hypothesis that metabolic derangements in cancer 
cachexia not only affect overall skeletal muscle mass but 
also affect swallowing muscle mass in particular, leading to 
OD. Recently, diagnostic criteria for sarcopenic OD were 
588 European Archives of Oto-Rhino-Laryngology (2021) 278:577–616
1 3
proposed, but remain difficult to apply in HNC patients 
[207]. The authors described that a definite diagnosis of sar-
copenic OD can only be obtained if imaging is consistent 
with a loss of swallowing muscle mass [207]. Unfortunately, 
imaging of swallowing muscles remains challenging. Only a 
few studies have managed to determine swallowing muscle 
volume through magnetic resonance imaging (MRI), com-
puted tomography scan, and ultrasound [208–210]. Swallow-
ing muscle function can be assessed more readily through, 
among others, tongue-pressure tests [211]. Besides evalu-
ating swallowing muscle function, Maeda and colleagues 
found other potential clinical predictors for the development 
of sarcopenic OD. The combination of performance status, 
ambulatory status, nutritional status, and low amount of oral 
intake can be used to screen patients at risk of developing 
sarcopenic OD following hospital admission [212]. Since 
the presence of cancer cachexia greatly influences treatment 
toxicity and patient-reported outcomes, screening for muscle 
wasting in HNC patients is recommended [213–215]. Body 
mass index (BMI) measurement cannot reveal a low muscle 
mass, in particular not when hidden by relative or absolute 
fat mass abundance. Ideally, a rapid screening method for 
body composition, such as bioelectrical impedance analy-
sis (BIA) would be suitable for this purpose. It has been 
shown that measurements of the fat-free mass index using 
BIA have a prognostic value [198]. In addition, dual-energy 
X-ray absorptiometry (DEXA) is minimally invasive and 
enables adequate information on body composition. For 
study purposes, the use of cross-sectional muscle area on 
computed tomography scans provides insight in skeletal 
muscle mass and quality [216]. Future studies are needed to 
further establish the relationship between skeletal muscle 
wasting and swallowing muscle wasting in the HNC popula-
tion. The treatment of cancer cachexia is considered further 
in "Treatment of cancer cachexia" section.
Psychosocial and economic impact 
of oropharyngeal dysphagia in head 
and neck cancer
Psychosocial impact
Psychosocial distress is defined as “a multifactorial unpleas-
ant experience of a psychological (ie, cognitive, behavioral, 
emotional), social, spiritual, and/or physical nature that 
may interfere with the ability to cope effectively with cancer, 
its physical symptoms, and its treatment”[217]. Psychosocial 
disruptions can have a significant impact on HRQOL [218], 
which reflects the patient’s perception of cancer impact on 
a broad range of well-being domains, including physical, 
social, and psychological [102]. HNC has been identified as 
the most psychologically traumatic cancer for patients and 
their caregivers and is listed as one of the cancers associ-
ated with high risk for depression [217, 219, 220]. In addi-
tion to common stressors related to cancer diagnosis and 
its associated anxiety, pain, fatigue, and fear of recurrence, 
HNC patients can experience profound changes in physi-
cal appearance, speech, voice, swallowing, hearing, breath-
ing, and high levels of symptomatology. These sequelae 
have detrimental effects on patients’ emotional well-being, 
self-identity and interpersonal relationships, and have pro-
found implications for their QOL [221]. Compared to other 
oncological populations, it is suggested that HNC patients 
experience higher levels of depression and anxiety [222], 
heightened sense of uncertainty and hopelessness [223], and 
are at higher risk of suicide [224]. Facial disfigurement and 
the stigma related to it represent principal sources of dis-
tress, insecurity and shame, progressively leading to social 
withdrawal [225, 226]. Eating difficulties are often associ-
ated with emotional and social losses for HNC patients who 
report feelings of embarrassment, frustration, anger, and 
anxiety related to food and mealtimes [227–229]. OD has 
also a significant effect on caregivers, who need to adapt 
their own diets and can experience high levels of distress 
related to mealtime preparation and feeding tube manage-
ment [230]. Changes in voice quality and speech intelligibil-
ity affect patients’ willingness to engage in communicative 
interactions and social activities [231, 232]. Evidence sug-
gests that such changes have further negative impacts on 
employment opportunities, ability to work and return to the 
workplace (see "Reimbursement of head and neck cancer 
related oropharyngeal dysphagia costs in European coun-
tries" section) [233, 234]. All these and further psychosocial 
stressors, like secondary head and neck lymphedema [235], 
shoulder dysfunction [236], ongoing concerns of cancer 
recurrence [237], sexual dysfunctions [238], the high finan-
cial impact of the disease [239], ultimately contribute to 
poor HRQOL outcomes for this patient population and their 
family and caregivers.
Psychosocial interventions have been demonstrated effec-
tive in improving HRQOL in different cancer populations 
[240, 241] and psychosocial support is recommended by 
international clinical guidelines for cancer care [45, 242, 
243]. Specifically for the HNC population, psycho-educa-
tional programs, cognitive behavioral training, psychother-
apy, group support, and pharmacological interventions for 
both patients and caregivers have been proposed [218, 244, 
245]. While the evidence supporting the effectiveness of 
such interventions is lacking [246], counseling and patient 
education, peer and social support are perceived as critical 
factors in alleviating psychological distress and increasing 
confidence. Referral to psychosocial health profession-
als, including psychologists, social workers, counselors, 
nurses, and psychiatrists, is recommended before, during 
and/or after cancer treatment and is advocated by national 
589European Archives of Oto-Rhino-Laryngology (2021) 278:577–616 
1 3
guidelines and policies for HNC [15, 247]. The role of 
online support groups is also recognized (see "Head and 
neck cancer patient perspective" section) [248]. Because 
HNC patients often underreport their concerns and suffering 
they may be more reluctant to accept psychosocial support 
[249]. Screening and ongoing monitoring for psychosocial 
distress are critical. Screening measures such as the Distress 
Thermometer [217], the Hospital Anxiety and Depression 
Scale [250], or the Brief Symptom Inventory-18 [251] are 
most widely used in cancer populations. HRQOL measure-
ments give a fundamental perspective on cancer treatment 
outcomes, by assessing the patient’s well-being over cancer 
trajectory [252]. Several validated questionnaires are rou-
tinely implemented in clinical practice to evaluate HRQOL 
in the HNC population [253]. These include general multid-
omain questionnaires, like the EORTC QLQ-H&N35 [107], 
the FACT-H&N [254], and the MDASI-HN [255], and ques-
tionnaires addressing specific HNC-related symptoms, for 
example, the MDADI [106] as described in "Screening and 
clinical assessment of oropharyngeal dysphagia in head and 
neck cancer" section. Addressing the psychosocial sequelae 
of HNC is paramount to improve patients’, carers’, and fami-
lies’ QOL. It is recommended to incorporate psychosocial 
interventions early into HNC care pathways with screening 
procedures implemented into clinical routine for early iden-
tification and management.
Reimbursement of head and neck cancer related 
oropharyngeal dysphagia costs in European 
countries
Acute in-hospital and long-term healthcare costs arise for 
HNC patients who have OD with their associated nutritional 
and respiratory complications. Charges also include direct 
non-healthcare expenditure, such as social costs, and indirect 
costs related to productivity loss, and intangible costs related 
to loss of income. A recent systematic review estimates the 
cost of OD as approximately €13.000 (approx. USD 14,900) 
in the acute phase of the disease and the expenditure related 
to an episode of aspiration pneumonia to be up to € 26.000 
(approx. USD 29,800) in patients with post-stroke OD 
[256]. However, no systematic reviews are available on costs 
related to OD associated with HNC and its main complica-
tions, with very few studies published in the area. Short-
term outcomes and costs of care after HNC surgery in the 
presence of OD is associated with a significant increase in 
costs during hospitalization with an increase of 2 days in the 
length of hospital admission for OD-related problems [257, 
258]. An additional study examined the association between 
quality of care, short- and long-term outcomes related to 
the HNC treatment, and costs in elderly patients (66 years 
and older; n = 2370) treated for laryngeal cancer. Costs 
included in-hospital, outpatient, and long-term healthcare 
costs during a 5-year follow-up period. They found lower 
OD-related healthcare costs in those patients who received 
a higher quality standard of care using evidence-based prac-
tices associated with quality indicators [259]. In addition, a 
2014 study reported an increase in OD related expenditure of 
USD 65,766 attributed to in-hospital, outpatient, physician/
supplier, hospice, home healthcare, and medical equipment 
costs incurred over a 5-year follow-up period [260]. In sum-
mary, there is emerging evidence on the strong impact of OD 
on health-related economic costs. There is an urgent need for 
specific studies to further define the independent effect of 
OD on the healthcare costs of patients with HNC.
Oropharyngeal dysphagia treatment in head 
and neck cancer
Bolus consistency modification
Bolus consistency modification is a compensatory strategy 
for HNC patients with OD following oncological treatment 
that has two main aims: (a) to maintain a safe way of oral 
hydration (by fluid thickening); and (b) to maintain patients’ 
nutritional status with texture modified foods. The preva-
lence of malnutrition is high in HNC patients with OD as 
described in "Cancer cachexia in head and neck cancer" sec-
tion [56]. Bolus consistency modification should be adapted 
to the mastication and swallowing ability of HNC patients, 
and include: (a) rheological adaptation; for fluids—viscosity 
and for solids—texture adaptation for safe swallowing, (b) 
nutritional adaptation to meet the nutritional requirements 
of HNC patients with OD, and (c) organoleptic adaptation 
to optimize taste, smell, appearance, and palatability of the 
food and fluids. These considerations should be applied sys-
tematically during the treatment of OD in HNC patients to 
improve their nutritional status and HRQOL [261]. But these 
considerations should also be applied to HNC patients who 
are still on the inpatient ward after, for example, a surgical 
intervention whereby stepwise reintroduction of oral food 
intake is often applied. In the majority of HNC patients, 
the modification of bolus consistency of solids and/or liq-
uids will be applied in conjunction with rehabilitative bio-
mechanical OD interventions (see "Head and neck cancer 
specific exercise treatment for oropharyngeal dysphagia" 
section) [262].
Fluid thickening (liquids)
Fluid bolus is characterized by its basic rheological property 
namely viscosity, which defines its resistance to flow. The 
effect of salivary amylase in the oral phase and shear thin-
ning (defined as the non-Newtonian behavior of fluids whose 
viscosity decreases under shear strain) during the pharyngeal 
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phase of swallowing are the two main factors affecting the 
safety and therapeutic effect of thickened fluids. Starch-
based (SB) and xanthan gum-based (XGB) thickeners are 
often used in diet modification for HNC patients with OD. 
However, the hydrolysis of SB components by α-amylase 
reduces the viscosity of the thickened drinks prior to swal-
lowing resulting in a negative treatment effect of OD (Fig. 1) 
[100, 263]. A White Paper from the ESSD concluded that 
there is evidence to suggest that increasing bolus viscosity 
can lower the risk of aspiration and that it is a valid manage-
ment strategy for OD [100]. Bolus consistency modification 
in HNC patients with OD can improve several pathophysio-
logical consequences without improving the actual swallow-
ing function. This can manifest, for example, as improving: 
(i) the bolus formation [264], (ii) impaired oropharyngeal 
bolus propulsion following treatment for oropharyngeal can-
cer at subsites such as the tongue base, pharyngeal wall, and 
soft palate or (iii) aspiration due to impaired upper respira-
tory tract closure and sensorial feedback in case of laryn-
geal dysfunction following (C)RT or partial laryngectomy. 
Nonetheless, there is a need for research to establish the 
‘optimal’ viscosity levels to prevent aspiration and improve 
the safety and efficiency of oral intake for HNC patients 
[154, 265]. Thickened fluids and altered consistency foods 
can also impact negatively on HRQOL (see "Psychosocial 
impact" section).
Previous viscosity classification models using descriptive 
textural names (‘nectar’, ‘honey’ or ‘spoon thick’) show a 
strong disagreement between health professionals regard-
ing the interpretation of these qualitative descriptors [266]. 
Different classifications of viscosity levels have emerged in 
recent years such as the National Dysphagia Diet (NDD) 
[267], the International Dysphagia Diet Standardisation 
Initiative (IDDSI) [268], and the Japanese Dysphagia Diet 
2013 (JDD2013) [269] all using different and arbitrary vis-
cosity levels and terminology. The ESSD proposes to go 
further than just the use of a descriptive classification of 
viscosity levels and therefore recommends that manufac-
turers of thickening agents also include the viscosity values 
in Système Internationale d’Unités (SI) units (mPa·s) into 
the labels of thickening agents [100, 270, 271](Fig. 2). The 
assessment of ‘optimal’ volume and viscosity level can be 
Fig. 1  Shear thinning and amylase resistance of a xanthan gum-based 
(XGB) and a starch-based (SB) thickening agent. Note the shear thin-
ning between 50 s−1 and 300 s−1 is quite comparable between XGB 
and SB agents; however, the reduction of viscosity caused by 30  s 
incubation with salivary amylase is much higher for the SB thicken-
ing agent
Fig. 2  The ESSD proposes to go further than just the use of a 
descriptive classification of viscosity levels and therefore recom-
mends that manufacturers of thickening agents also include the vis-
cosity values in Système Internationale d’Unités (SI) units (mPa  s) 
into the labels of thickening agents as presented by this example
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done under direct view using VFSS or FEES (see "Vide-
ofluoroscopic swallow study " and "Fiberoptic endoscopic 
evaluation of swallowing"  sections).
Texture modified foods (solids)
The level of scientific evidence of the therapeutic effect of 
texture modified foods in HNC patients is still low [272]. 
Several food textural and rheological properties, such as 
‘elasticity’, ‘hardness’, ‘gumminess’, ‘springiness’, ‘creami-
ness’, ‘crispness’, ‘brittleness’, ‘chewiness’, ‘adhesiveness’, 
and ‘cohesiveness’, are used to describe solid food boluses. 
A texture modified diet should include both a nutritional 
adaptation (caloric and protein content) and an organoleptic 
adaptation (smell, taste, appearance, etc.) [261]. It is argued 
that the clinical strategy called ‘The Minimal-Massive 
Intervention’ (MMI) provided strong clinical benefits in 
elderly patients and could also be applied to HNC patients 
[273]. Before promoting the MMI in oncological popula-
tions, additional research is needed. The Test of Masticat-
ing and Swallowing Solids (TOMASS) was developed as 
a quantitative assessment of solid bolus ingestion [274]. It 
measures the number of masticatory cycles and swallows per 
bite, and time per bite, masticatory cycle and swallow [274]. 
The TOMASS was not validated to prescribe the optimal 
solid texture level but it can certainly contribute to making 
a patient-tailored clinical OD management plan for solid 
bolus ingestion.
Hidden risks of bolus consistency modification
The adherence to thickeners in general and XGB thicken-
ers in particular is very low due to unpalatability leading 
to an increased risk of dehydration [262, 275, 276]. Fur-
thermore, the exclusion of some solid foods due to the dif-
ficulty to adapt them to an optimal texture might decrease 
the nutritional content of meals [277]. Furthermore, patients 
treated with (C)RT may have difficulties with texture modi-
fied foods, as the taste and texture of modified foods can 
be less well tolerated by HNC patients with nausea, taste 
disturbances, mucositis, oral candida, and xerostomia [278]. 
Hydration and nutrition monitoring as well as clinical super-
vision of the potential respiratory tract complications of OD 
are essential for patients requiring bolus consistency modifi-
cation (see  "Complications due to oropharyngeal dysphagia 
in head and neck cancer", "Cancer cachexia in head and neck 
cancer", and "Treatment of cancer cachexia" sections).
Head and neck cancer specific exercise treatment 
for oropharyngeal dysphagia
The goal of swallowing exercises is to change swallow phys-
iology through targeting strength and/or range of movement 
of muscles and to improve sensory feedback responsible for 
motor programming and execution to improve swallowing 
safety and efficiency. Several different exercises are used 
in clinical practice targeting the oral tongue, lips, base of 
tongue, jaw, soft palate, larynx, and pharynx. Swallowing 
exercises are differentiated from compensatory strategies 
that alter swallowing and facilitate improvement whilst an 
individual is eating or drinking. The use of compensatory 
strategies such as a chin tuck, head turn, or supraglottic swal-
low may immediately facilitate safer swallowing during a 
given moment, but are unlikely to create lasting changes to 
the physiology of the swallow mechanism [279]. Swallowing 
exercises were traditionally provided as part of rehabilitation 
after completion of all HNC treatment, although recent lit-
erature has questioned the benefit of these exercises provided 
months after cancer treatment [280]. Over the last decade, 
support from clinical researchers for the use of prophylactic 
swallowing exercises has grown, centered on the premise 
that strength-based and/or range of movement exercises tar-
geted at the swallowing muscles may prevent muscle atrophy 
and reduce or delay the impact of RT-induced fibrosis [69, 
281–283]. Despite good biological plausibility, the most 
recent Cochrane systematic review found insufficient high-
quality empirical evidence to support the routine use of pro-
phylactic swallowing exercises [284]. A separate review [57] 
using a health behavior change model to analyze a similar 
body of evidence to the Cochrane review questioned whether 
other factors such as patient adherence to exercises may be 
contributing to poor results in efficacy trials of prophylactic 
swallowing exercises. The findings from both these reviews 
call for larger, methodologically robust trials that address 
previous shortcomings such as poor patient adherence to 
exercises and the type and timing of outcomes. Thus based 
on the currently existing evidence, it remains uncertain 
whether patients who undertake prophylactic swallowing 
exercises experience better swallowing outcomes after HNC 
treatment compared with those who do not.
A meta-analysis review exploring OD treatment across 
the pathway of care for people with HNC found evidence 
for some improvements to selected aspects of swallowing 
function and jaw opening for exercises before and after 
oncology treatment, but no evidence for improved QOL 
[285]. These authors likewise advised on the need for further 
well-designed trials. Since these reviews, a few randomized 
clinical trials of swallowing exercise interventions have been 
published and/or are currently underway each with differing 
foci. These include a theory-based behavior change approach 
to swallowing exercise interventions [286], prophylactic 
exercises delivered via different methods including home-
based, home-based with counseling via an App, face-to-face 
therapy [287], and swallowing exercises with respiratory 
muscle training randomized to two groups of patients; before 
CRT or immediately after treatment completion [288].
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It is clear from the above, that there are a number of reha-
bilitation/prehabilitation programs available [285] and sev-
eral novel developments on the horizon for which a useful 
overview is provided by Cuicci and colleagues [289]. Two 
of the more commonly used programs include Pharyngocize 
[283], a standardized high-intensity swallow exercise pro-
gram including exercise and diet modification administered 
daily by the therapist throughout the duration of (C)RT; and 
the McNeil Dysphagia Program [290] which incorporates 
principles of progressive resistance and load. A bolus driven 
approach is used to systematically increase oral intake across 
a variety of food textures whilst simultaneously training 
swallowing. The use of adjunctive device-driven exercise 
protocols that include biofeedback, such as the Iowa Oral 
Performance Instrument (IOPI) [291] or expiratory muscle 
strength training [292] may also offer some benefit. At pre-
sent, we have limited high-quality evidence from empirical 
studies to inform practice around the best timing and the 
optimal dose for swallowing exercises, but research in this 
field is at an exciting phase and continues to incrementally 
improve our understanding and knowledge of the benefit of 
swallowing exercises in people with HNC. Furthermore, we 
are entering a new era of technology and practice advance-
ment with many research innovations emerging [289]. The 
choice of potential exercise interventions for clinicians 
working with this population of patients is therefore quite 
varied. Given the rapidly changing landscape within this 
field, it is important that decisions are made on the basis of 
best available evidence together with what is most feasible 
and acceptable for individual patients within the context of 
their care.
Oral health in head and neck cancer
Prevention and treatment of dental and jaw-related problems 
deserve special attention as they affect the health of HNC 
patients in multiple dimensions including the swallowing 
function. Osteoradionecrosis (ORN) is one such problem 
which causes significant morbidity, even though a decreased 
incidence is reported since the introduction of IMRT [293]. 
ORN usually presents as exposed necrotic bone, ulcera-
tion, suppuration, pain, lymphadenopathy and/or paresthe-
sia [294]. The mandible is most commonly affected due to 
the dense bone and its vulnerable blood supply [295]. HNC 
patients who develop ORN have usually received a RT dose 
of 60 Gy + [296]. A systematic review found that while the 
incidence of ORN after post-irradiation tooth extractions 
is low, the extraction of mandibular teeth within the radia-
tion field in patients who received a radiation dose higher 
than 60 Gy represents the highest risk of developing ORN 
[296]. In the majority of cases, ORN develops within the 
first 3 years (74%) after RT but it can also occur long-term 
post-RT. Tooth extraction causes approximately 50% of the 
ORN cases and 30% occur spontaneously following HNC 
treatment [296, 297]. Risk factors for ORN include trauma 
from dental extractions, ill-fitting dentures, and periodon-
tal infection affecting the tooth furcation and alveolar bone 
[298]. The furcation is situated between the roots of pos-
terior teeth, normally covered in bone. Furcation exposure 
due to periodontitis may result in infection in this difficult to 
access area. Monitoring and early intervention to maintain 
oral health is advised with a careful periodontal or radio-
graphic examination. Treatment modalities for ORN range 
from conservative (oral rinses, irrigation, and antibiotics) 
to surgical resection of the jaw depending on the extent 
and severity of the problem [294, 299]. The use of hyper-
baric oxygen may be considered, but supporting evidence is 
weak [300, 301]. Following RT, dental extractions from the 
bone which has received high dose radiation should only be 
undertaken if unavoidable—endodontic treatment and dec-
oronation should be considered first [302]. In the context of 
oral health and dental rehabilitation, treating periodontal dis-
ease and restoring occlusal function are important for masti-
cation of food and bolus preparation, facilitating nutritional 
intake, and reducing the risk of aspiration of food and/or of 
oral micro-organisms into the respiratory tract [303–306].
Dry-mouth may compromise oral health in this popula-
tion. It affects up to 85% of HNC survivors following RT 
with the salivary glands in the field of radiation [307, 308]. 
Dry-mouth and poor compliance with regular dental attend-
ance, OH, diet, and daily fluoride use are significantly asso-
ciated with the development of dental decay requiring tooth 
extraction following HNC treatment [309]. ORN prevention 
is therefore an important point of attention and is preferably 
initiated with oral care pre-(C)RT [310, 311]. An interesting 
but not unexpected development is that the reported inci-
dence of ORN has decreased from 20–30 to 4–8% in recent 
studies using IMRT [312]. In addition to IMRT positioning 
or shielding stents can also protect healthy tissues, includ-
ing salivary glands, alveolar bone, and masticatory muscles 
[302]. Pre-RT extraction of teeth of questionable progno-
sis in the high-dose RT field is recommended [313, 314]. 
Healthy and unerupted teeth covered by bone are usually 
retained [313]. Decisions regarding extractions also require 
an assessment of the likely future compliance of the HNC 
patient with oral care [299, 309, 315]. If there is no residual 
salivary gland function, salivary substitutes can be explored 
for oral-lubrication to reduce oropharyngeal dryness and 
improve HRQOL [316]. If there is some residual function, 
salivary gland stimulants (e.g. sugar-free chewing-gum, 
pilocarpine/cevimeline) may give some relief [317, 318]. 
It is recommended that dentate patients with HNC avoid 
saliva-stimulating products containing citric acid because it 
can support dental erosion. A number of HNC patients also 
report long-term preference for plain tap water as saliva sub-
stitutes provide only short-term relief [315]. A high energy, 
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carbohydrate diet may cause rampant dental decay due to the 
dry-mouth related shift to cariogenic oral microorganisms. 
It is strongly recommended to avoid sugar in the diet, use 
toothpaste that has a higher fluoride concentration (4%) and 
to carry out meticulous plaque removal long-term post-RT 
in HNC patients to prevent further dental decay [319, 320]. 
Attention should also be paid to special situations such as 
limited access to posterior teeth due to trismus arising from 
reduced flexibility or fibrosis of masticatory muscles and 
buccal mucosa following (C)RT.
Excellent OH is recommend using a small-headed pediat-
ric, end-tufted or interdental toothbrush, floss/airflosser, and 
Waterpik® as interdental food stagnation is common with 
dry-mouth, increasing the risk of dental decay and food/
bacteria aspiration [304, 305, 319, 321]. Products like chlo-
rhexidine liquid (0.2% or 0.1%) may be used as a brush-on 
to reduce staphylococcus mutants levels and control gingival 
inflammation [322, 323]. Careful subgingival scaling and 
furcation monitoring during oncological follow-up are nec-
essary to lower the risk of ORN [316].
Oral function of the HNC survivor should be carefully 
assessed post-surgery/RT to determine the need for den-
tal rehabilitation. A shortened dental arch (SDA) with 20 
functioning units seems to maintain masticatory function, 
aesthetics, satisfaction, psychosocial ability, occlusal sup-
port, jaw stability, tactile perception, speech-articulation, 
and taste [324]. It is suggested that patients with a SDA 
have an acceptable level of OH-related QOL [325]. Dentures 
should be made carefully with stability, retention, and load 
distribution across the tissues as surgical defects and RT-
induced fibrosis increase the complexity of denture design 
[326, 327]. Osseointegrated dental implants can be life-
transforming for HNC survivors suffering from dry-mouth 
or following major surgical resection, but studies suggest 
that implant survival is strongly influenced by RT. Success-
ful implant placement into irradiated bone was reported by 
Pompa and colleagues [328]. However, 76% of HNC irradi-
ated patients in this study received 36 Gy with only 24% 
receiving 60 Gy. Significantly better implant survival in non-
irradiated bone has been reported [329]. Optimal timing of 
implant placement in HNC patients planned for (C)RT is 
controversial. Implants may be placed pre-RT at the time of 
cancer surgery or post-RT [330]. Implant placement at the 
time of surgery facilitates osseointegration pre-RT reduc-
ing the risk of late complications (e.g. ORN) [303]. How-
ever, the risk of inappropriate implant positioning during 
oncological surgery has been described making subsequent 
prosthodontic treatment more complex [331]. A review 
comprising 416 patients who had a fibula-free-flap recon-
struction following segmental mandibulectomy reported that 
postoperative RT was a contra-indication for dental implants 
due to the high risk of ORN [299]. Furthermore, the authors 
concluded, “secondary dental implant placement involves 
multiple surgeries, hospitalizations, and financial burden. 
Primary implant placement during the time of tumor resec-
tion, either in native or reconstructed non-irradiated bone, 
offers an opportunity for implant supported restorations to 
the oral cancer patient” p.1734 [299]. Finally, it is recom-
mended to discuss dental rehabilitation and long-term OH 
early during MDT meetings and subsequent treatment deci-
sions should be made on a case-by-case basis [315].
Treatment of trismus following (chemo)
radiotherapy
The normal range of Inter-incisal Mouth-Opening (IMO) 
is 40–60 mm. Mouth opening restricted to 35 mm or less 
is considered to be trismus [332, 333]. Pre-RT IMO is a 
significant indicator for the development of trismus post-
RT [334]. Trismus is related to masticatory muscle dam-
age, temporomandibular articulation (TMA) damage, fibrous 
ankylosis and/or rapid growth of scar (connective) tissue. 
This condition can be very painful, resulting in a vicious-
cycle where more rapid and forceful attempts at mouth open-
ing can generate more reflex contraction thus generating 
increased pain [335]. However, also without any movement, 
a degenerative TMA may occur with muscle atrophy and 
shortening of masticatory muscle fibers [336]. In assess-
ment, reduction of mouth opening due to tumor recurrence 
should always be excluded first [337]. The prevalence of 
trismus in HNC patients is reported at 25.5% following con-
ventional RT versus 5% after IMRT and 30.7% using (C)
RT and 3D-CRT [338]. The prevalence of trismus increases 
with increasing doses of RT to the masticatory structures 
[337]. It has been concluded that novel RT modalities may 
decrease the prevalence and severity of trismus compared to 
conventional RT [334, 337]. However, despite better-focused 
RT dose and improved screening, progressive masticatory 
muscle stiffness and limitation of mouth opening remain a 
common complication [339]. It is suggested that limiting 
dose to these structures to ≤ 40 Gy for tumors not invad-
ing the masticatory muscles may improve treatment-related 
sequelae [340].
Limited mouth-opening directly affects many aspects of 
daily life such as taste, salivation, mastication, swallowing, 
eating, dental health, pain in head and neck, speech, voice, 
communication, etc. [341]. Trismus can have serious health 
and HRQOL implications, including those of nutritional 
nature due to impaired mastication if food is not properly 
broken down also posing an aspiration and choking risk 
during swallowing (see "Cancer cachexia in head and neck 
cancer", "Bolus consistency modification", and "Treatment 
of cancer cachexia" sections). Furthermore, difficulty during 
speaking, compromised OH and delivery of dental care are 
other consequences of trismus [335, 342, 343]. Mouth open-
ing post-RT decreases on average by approximately 20% 
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compared to mouth opening pre-RT [337]. Regular measure-
ments of maximal mouth opening are needed to predict the 
development of trismus [344]. The risk of developing post-
RT trismus can be related to a variety of factors including 
tumor location, RT dose to the primary tumor, RT dose to 
the muscles of mastication, age, gender, and pre-RT mouth-
opening measurements [344].
Early intervention is essential to prevent long-term dis-
ability [337, 345]. The prevention of trismus, rather than its 
treatment, is the most important objective [337, 346, 347]. 
There should be regular post-RT reviews and measurement 
of IMO with dental or SLP professionals. Treatment of 
trismus can be conservative (with either medical or physi-
cal therapy) or surgical. Exercise therapy is the mainstay 
of treatment and should start as soon as possible after (C)
RT. Prosthetic RT devices, including positioning and shield-
ing stents, may be considered to reduce RT-induced tissue 
morbidity [302]. Early trismus management using exercise, 
physiotherapy, massage, slow motion, and wide movements 
avoiding pain, wood-sticks or  TheraBite® is recommended. 
The use of structured exercise with the jaw-mobilizing 
device  TheraBite® seems to be beneficial for patients with 
trismus independent of time since the oncological treat-
ment [348]. Exercises should be performed intensively on a 
daily basis. The aim is to provide a better oral preparatory 
swallowing phase whilst improving speech and articulation 
[283, 349]. Passive motion applied several times per day is 
suggested as more effective than static stretching providing 
a significant reduction in inflammation and pain. Ongoing 
exercise during the HNC person’s lifetime is recommended 
since fibrosis will continue to progress as soon as exercises 
stop [283, 336, 342, 349, 350]. A systematic review of the 
effects of exercise therapy for trismus secondary to HNC 
reported considerable differences in mouth opening ranges 
and no evidence that any stretching technique was superior 
for either prevention or treatment of trismus [351]. Other 
interventions that decrease the severity of cancer treatment-
related trismus include pentoxifylline to improve microcir-
culation and tissue oxygenation [352]. However, reported 
compliance with pentoxifylline appears to be limited by the 
effects of nausea [353]. Botulinum toxin injection may be 
used to reduce pain associated with trismus, although it does 
not improve jaw mobility [354]. Coronoidectomy may be 
used to increase the range of jaw motion and mouth opening 
[355]. However, controlled studies on the efficacy of these 
interventions are lacking in this area [338].
Surgical treatment of oropharyngeal dysphagia 
in head and neck cancer
As described in the previous sections of this paper, OD in 
HNC patients may be the result of alterations in the upper 
aerodigestive tract caused by the disease and/or oncological 
treatment modalities. Dysfunction of the UES is often 
multifactorial in HNC patients and may be due to (C)RT, 
pharyngeal closure technique and the extent of additional 
pharyngeal mucosa resection in case of TLE, and postopera-
tive complications [69, 356–358]. The incidence of cervi-
cal esophageal strictures following HNC treatment varies 
between 5 and 15% [359–361]. Since 1951, studies have 
reported several surgical and less-invasive treatments for 
UES dysfunction. The effectiveness of each treatment in 
the management of OD, due to various etiologies including 
HNC and its oncological treatment, is still subject to debate 
[362–365]. A malfunctioning UES can be diagnosed as 
described under previous sections of this paper (see  "Vide-
ofluoroscopic swallow study" and "Manometry"). To date, 
there are too few large studies describing the indications, 
side effects, and results of the different surgical modalities 
for UES dysfunction in HNC patients. The Dutch national 
guideline on OD was published in 2017 [365]. The guideline 
was developed using robust methodological techniques [366] 
and the studies on surgical treatment for OD were obtained 
using separate systematic literature searches on the follow-
ing: myotomy of the UES, botulinum toxin injection in the 
UES, and dilatation of the UES or proximal esophagus stric-
tures. All studies on myotomy and botulinum toxin injection 
in the UES were excluded based on methodological quality. 
For evidence on dilatation of the UES, only one article was 
judged to have sufficient methodological quality [367]. This 
study investigated non-HNC patients with OD following dil-
atation of the esophagus by means of a “through-the-scope 
balloon”. However, these results cannot simply be extrapo-
lated to a HNC patient population and further research with 
HNC populations is required. Recent systematic reviews 
confirmed these findings of insufficient evidence to guide 
clinical practice for HNC patients [362–364]. Despite the 
uncertain evidence, myotomy of the UES, botulinum toxin 
injection in the UES, and dilatation of the UES or proxi-
mal esophagus strictures remain frequently applied surgical 
modalities in the management of OD in HNC patients fol-
lowing oncological treatment [363, 365].
Treatment of HNC with (C)RT can result in strictures of 
the cervical esophagus, often at the level of the cricopharyn-
geal segment [368]. UES myotomy is one of the main surgi-
cal options for the treatment of OD in HNC. It can be per-
formed transorally or via an external transcervical approach. 
Transoral CO2 laser-assisted myotomy is typically preferred 
because it is deemed “simpler”, safer and less invasive than 
the external approach and is considered as effective as an 
external myotomy [369]. All muscle fibers are cut using the 
CO2 laser until the buccopharyngeal fascia is reached. Some 
surgeons leave the wound open [362], others apply fibrin 
glue [368] or suture the mucosa over the incised muscle fib-
ers to prevent salivary leakage causing mediastinitis [370]. 
If endoscopic myotomy cannot be performed due to trismus 
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or pharyngeal strictures an external myotomy can be con-
sidered. A left-sided external approach is preferred because 
the left recurrent laryngeal nerve is longer than the right and 
has a more complex route, making it more prone to injury. 
However, if unilateral vocal fold paralysis already exists, it is 
wise to select that paralytic side to avoid the paralysis of the 
healthy vocal fold. Despite the lack of high-quality studies, 
there is some evidence to justify the use of UES myotomy 
in HNC patients. UES myotomy significantly improved 
swallowing outcomes of HNC patients with OD following 
organ preservation therapy [362]. Research by Silver and 
colleagues also revealed recovery of OD in 90% of their 
HNC patients following CO2 laser myotomy of a post-(C)
RT stenosis at the UES level [368].
Postoperative swallowing rehabilitation is recommended 
[364]. However, as described in previous sections of this 
paper, it seems less likely that OD in HNC patients is only 
the result of an isolated UES dysfunction. There is certainly 
literature available that can support the use of such surgi-
cal UES interventions in well-selected HNC patients. We, 
therefore, recommend that the indication for surgery should 
be based on a robust swallowing assessment using at least 
an instrumental assessment tool as described under "Vide-
ofluoroscopic swallow study ", "Fiberoptic endoscopic eval-
uation of swallowing", and Manometry" sections, a patient 
self-report tool (see " Screening and clinical assessment of 
oropharyngeal dysphagia in head and neck cancer" ), and a 
nutritional assessment (see  "Cancer cachexia in head and 
neck cancer" and "Treatment of cancer cachexia" sections). 
Such a multi-dimensional swallowing assessment can help 
in predicting the chance of success of a particular surgical 
modality for a patient and is also essential in the risk–benefit 
estimation of such interventions. Adverse events following 
UES surgical interventions, such as severe recurrent aspira-
tion pneumonia due to severe gastroesophageal reflux fol-
lowing UES myotomy in the presence of a dysfunctional 
lower esophageal sphincter have been reported [371, 372]. 
The most important adverse event of such UES interven-
tions is an esophageal perforation accompanied by medi-
astinitis, sepsis, and a high risk of death [363]. Fortunately, 
the chance of such an adverse event is low in the hands of 
experienced surgeons and carefully selected patients. Surgi-
cal interventions have also been described for HNC patients 
with very severe and difficult-to-treat aspiration. In particu-
lar, patients with severe OD-related respiratory tract compli-
cations may benefit from surgical interventions such as vocal 
fold medialization techniques in case of vocal fold paralysis 
[373] (see "Management of oropharyngeal dysphagia as an 
adverse event and in case of palliation" section), a trache-
otomy using cuffed tracheostomy tubes (see "Tracheostomy 
and oropharyngeal dysphagia in head and neck cancer"  and 
"Complications due to oropharyngeal dysphagia in head and 
neck cancer" sections), laryngeal suspension surgery [370, 
375, 374], and in selected cases laryngotracheal separation 
or a TLE [376–379]. These are, of course, interventions 
that are considered ’last resort surgical interventions’ for 
the treatment of severe life-threatening OD. The number of 
studies on laryngeal suspension surgery and laryngotracheal 
separation in HNC patients is very limited and it mainly con-
cerns smaller case series with a low level of evidence [370, 
374–376]. The body of literature on functional laryngectomy 
for end-stage OD in HNC patients is slightly more extensive 
[377–379]. These surgical interventions do not guarantee an 
overall improvement of the swallowing function nor a nor-
malization of oral intake without feeding tube dependency. 
Again, it is essential to make a multidisciplinary risk–benefit 
estimation of such interventions and to discuss the adverse 
events with the patient during informed consent.
Treatment of cancer cachexia
The multifactorial underlying mechanism of cancer cachexia 
requires multimodal treatment strategies. The main chal-
lenge for HNC patients is meeting sufficient oral intake 
requirement levels. Different HNC treatment modalities 
require different nutritional approaches [380, 381]. Postop-
eratively a nasogastric feeding tube (NGT) is often inserted 
for a short period of time (10 days) to optimize wound heal-
ing and to bridge a period of OD and/or odynophagia. Nutri-
tional guidance during (C)RT of locally advanced head and 
neck tumors is more complex since maintaining sufficient 
oral intake is challenging due to high toxicity rates. Side 
effects, including, amongst others, mucositis [382], xerosto-
mia, sensory changes, pain, OD, nausea, and vomiting [383, 
384] lead to temporary tube feeding (TF) dependency in 
37–74% of the patients undergoing CRT [385–387]. Main-
taining good nutritional status and preventing weight loss 
have been associated with improved treatment tolerance, 
reduced risk of complications and associated therapy delay, 
increased response rate to (C)RT and higher survival rates 
[388–390]. Additionally, taking into account the phenom-
enon of sarcopenic OD, accurate nutritional support is of 
utmost importance. The additional value of dietary coun-
seling and nutritional support in HNC is clear [391]. How-
ever, the optimal type of tube (NGT or a gastrostomy) and 
timing of insertion (prophylactically or reactively) in HNC 
patients undergoing (C)RT remains controversial since high-
quality randomized trials are lacking [392]. NGTs are often 
considered to be uncomfortable, impeding oral intake due 
to pharyngeal irritation, and can be associated with reduced 
HRQOL compared to gastrostomy [393, 394]. Therefore, 
a gastrostomy is considered superior to a NGT when TF 
is required for a longer period of time. Gastrostomy tube 
insertion is recommended when TF extends beyond the 
expected use for 4–6 weeks [381, 395, 396]. Gastrostomy 
tubes may be inserted before the start of concurrent (C)RT 
596 European Archives of Oto-Rhino-Laryngology (2021) 278:577–616
1 3
(i.e. prophylactically). Having a gastrostomy in situ can 
facilitate immediate initiation of TF when necessary and 
enables direct administration of fluids in case of nephro-
toxicity. Additionally, this timing prevents the risk of 
treatment-induced neutropenia or mucositis complicating 
tube insertion. This immediate action could prevent further 
weight loss and organ damage. In addition, a better patient 
adherence to prophylactic TF might be expected compared 
to reactive feeding tube placement [397]. However, a gas-
trostomy is accompanied with complication rates of about 
3.3–19% [398, 399] and between 9 and 47% of the prophy-
lactic gastrostomies are never used [387, 400]. Furthermore, 
prophylactic gastrostomy insertion has been argued because 
it might lead to long-term OD, considering the “use it or lose 
it” principle regarding the swallowing mechanism [336, 401] 
but high-quality randomized trials to prove this theory are 
not available and other studies have shown no relationship 
between prophylactic gastrostomy and long-term swallowing 
function [402, 403]. Right now, high-quality evidence on the 
advantage of prophylactic gastrostomy placement in HNC 
patients undergoing (C)RT is lacking and routine prophylac-
tic gastrostomy in all these patients is certainly not advised. 
However, pre-(C)RT prophylactic gastrostomy placement in 
patients with a high risk of or pre-existing malnutrition and 
OD seems to be of added value, so that their survival will not 
be compromised by interrupting the (C)RT for reactive gas-
trostomy placement. Prediction models to identify patients 
requiring prophylactic gastrostomy insertion are currently 
under development [387, 404].
Catabolic effects on the skeletal muscles and poten-
tially also on swallowing muscles in cancer cachexia, are 
not entirely reversible using conventional nutritional sup-
port. Besides, providing sufficient calories and high-quality 
proteins, specific nutrients including eicosapentaenoic acid 
(EPA) and vitamin D have been investigated for their added 
value in cancer cachexia and previous pilot studies warrant 
further investigation in appropriately powered randomized 
clinical trials [405–407]. Timing of targeted nutritional 
supplementation is also important to consider to stimulate 
synergistic nutritional effects but to avoid adverse events 
from (C)RT [408]. More attention should be paid to optimize 
the nutritional status during the pretreatment as well as the 
recovery phase.
Next to nutritional support, skeletal muscle stimulation is 
important to combat systemic muscle catabolism. In HNC 
patients, resistance training of several skeletal muscles 
appeared feasible during (C)RT [409, 410]. Due to small 
study populations, the evidence is not clear on whether this 
resistance training actually leads to improved survival rates, 
but there seems to be a positive effect on HRQOL. Ideally, 
the physical exercise program is integrated into standard 
care to increase patient adherence to exercise. In case of 
functional deterioration during (C)RT, which complicates 
physical capacity, neuromuscular electrical stimulation 
might be considered as an alternative intervention for resist-
ance exercises [411] but requires further investigation and 
specification of skeletal muscle groups.
Management of oropharyngeal dysphagia 
as an adverse event and in case of palliation
The tumor itself may cause impaired swallowing function or 
impaired bolus passage, but swallowing can also be affected 
by adverse effects of the HNC treatment (surgery, RT, CRT, 
or combinations thereof—multimodality treatment) (see 
Pathophysiology and mechanisms of oropharyngeal dys-
phagia). OD with and without aspiration may occur due 
to changes in the anatomy, tissue properties, and sensory 
input of the oropharyngolaryngeal tract (cranial and cervi-
cal nerves VII, IX-XII, V2, V3, C1 C2) [69, 412, 413]. The 
extent of the malfunction depends on the size and location 
of the tumor as well as on the resected area, the reconstruc-
tion method, the extent of sensory reinnervation, and the 
application of postoperative (C)RT [414, 415]. For exam-
ple, maxillary sinus tumor excisions and velar surgery may 
leave oronasal or oromaxillary fistulae affecting oral bolus 
containment, velopharyngeal junction closure, pharyngeal 
pressure generation, and speech production. Intraoral pros-
thetic rehabilitation is often beneficial in this context and 
may improve the impaired oral bolus containment, velo-
pharyngeal junction closure, pharyngeal pressure genera-
tion, and speech production [292, 417, 416]. Also therapy-
induced facial nerve paresis, for example as an adverse 
event following an extended parotidectomy or excision of a 
skull-base or temporal bone tumor, may result in impaired 
stomatognathic functions, such as mastication, swallowing, 
and suction. Neuromuscular re-education exercises, surface 
electromyographic biofeedback (sEMG), chemodenervation 
or dynamic surgical facial reanimation in case of a sacri-
ficed facial nerve may be beneficial [418]. Neck dissections 
sacrificing the hypoglossal nerve, mandibular branch of the 
facial nerve, mylohyoid branches of the trigeminal nerve or 
the auricular branch of the facial nerve may also result in OD 
often with aspiration. Supraglottic laryngectomy extending 
to tongue base or arytenoid level is also accompanied by an 
increased risk of aspiration [419]. Standard pre- and post-
oncological treatment assessment of swallowing to identify 
the nature and severity of OD as described in "Videofluoro-
scopic swallow study ", "Fiberoptic endoscopic evaluation 
of swallowing", and Manometry" sections are recommended 
in the context of best practice [88] and OD interventions 
are often indicated (see "Bolus consistency modification" 
and "Head and neck cancer specific exercise treatment for 
oropharyngeal dysphagia"). Nowadays, in the case of (C)RT 
for advanced HNC, IMRT appears to be significantly benefi-
cial in sparing swallowing function without compromising 
597European Archives of Oto-Rhino-Laryngology (2021) 278:577–616 
1 3
survival due to dose reduction to swallowing structures, 
as described in "Pathophysiology and mechanisms of oro-
pharyngeal dysphagia", Oral health in head and neck cancer" 
and " Treatment of trismus following (chemo)radiotherapy", 
[420]. In addition, acute radiation-associated dysphagia 
(ARAD) also exists and is well documented in the literature 
[357]. Persistent or late OD-inducing conditions comprise 
ORN, dental decay, trismus, xerostomia, stenosis, fibrosis, 
etc. The characteristics of ARAD may include silent aspira-
tion and pharyngeal residue [69]. An intensive ‘boot camp’ 
type approach to treatment using sEMG biofeedback and 
bolus-driven therapy such as the McNeil Dysphagia Program 
has been described in Head and neck cancer specific exercise 
treatment for oropharyngeal dysphagia" section. In case of 
severe life-threatening posttreatment intractable aspiration, 
surgical options to separate the alimentary and respiratory 
tracts may be considered [421] (see "Surgical treatment of 
oropharyngeal dysphagia in head and neck cancer section). 
Furthermore, as vocal fold paralysis from vagal nerve dam-
age may contribute to aspiration risk as well [422], post-
treatment vocal fold medialization techniques to compensate 
the vocal fold closure gap may reduce aspiration [423] (see 
"Surgical treatment of oropharyngeal dysphagia in head and 
neck cancer" section). Vocal fold augmentation using hyalu-
ronic acid under topical anesthesia to facilitate laryngeal clo-
sure can also be considered for the palliative patient popula-
tion, as this may improve respiratory tract clearance, reduce 
aspiration risk, improve voice function, and HRQOL [424]. 
In addition, more permanent solutions such as laryngeal 
framework surgery or permanent injection augmentation 
with material such as polydimethylsiloxan may be consid-
ered in the context of palliative treatment too. Furthermore, 
trismus is a common adverse event following oncologi-
cal treatment of the area of the masticatory structures and 
rehabilitation is very relevant in the HNC population and 
described in " Treatment of trismus following (chemo)radi-
otherapy" section. In general, palliative OD rehabilitation 
focuses on the recovery of dignity, facilitating the person to 
have control within their physical limitations [425]. Several 
interventions described above can also be of added value 
for HNC patients in a palliative care setting. Instrumental 
swallowing assessment remains of great importance in the 
palliative HNC patient population as well to guide decision-
making for HRQOL and to support patient autonomy (see 
"Videofluoroscopic swallow study ", "Fiberoptic endoscopic 
evaluation of swallowing", and Manometry" sections). Fol-
lowing informed consent where patients acknowledge risks 
associated with oral intake, the palliative or non-palliative 
HNC patient may decide to continue to eat and drink without 
any restrictions as described in "Ethical issues, informed 
consent, and the right to refuse oropharyngeal dysphagia 
treatment" section. Along with standard interventions, fas-
tidious OH may reduce aspiration pneumonia and enhance 
HRQOL (see "Complications due to oropharyngeal dyspha-
gia in head and neck cancer" and "Oral health in head and 
neck cancer" sections) [426]. Finally, palliative TF or enteral 
feeding and a palliative tracheostomy clearly have a place 
in the care offered for these patients and are not necessar-
ily contraindicated (see "Ethical issues, informed consent, 
and the right to refuse oropharyngeal dysphagia treatment" 
section).
Oropharyngeal dysphagia following total 
laryngectomy
TLE is a surgical procedure that consists of removing the lar-
ynx and separating the airway and digestive tract. It is used 
as a treatment for advanced-stage laryngeal and hypopharyn-
geal cancer. If necessary, a TLE can be carried out in combi-
nation with a partial or total pharyngectomy or even with an 
esophagectomy. In the case of the latter two, a neopharynx is 
created by closing the pharyngeal defect with different types 
of pedicled or free flaps or with a gastric pull up. Preserva-
tion of swallowing and restoration of speech are important 
additional goals. OD is a common symptom following TLE 
and its frequency ranges from 10 to 72% [427–429]. The 
main complaints reported by TLE patients are regurgita-
tion even into the nasal cavity, food sticking in the throat, 
pharyngeal globus sensation, or a prolonged mealtime [357, 
430, 429]. The development of OD following TLE may be 
caused by multiple factors such as RT (primary (C)RT fol-
lowed by salvage TLE or TLE with postoperative (C)RT), 
the closure technique to create a neopharynx, the extent of 
additional pharyngeal mucosa resection, and postoperative 
complications [357, 430–432]. Swallowing assessment in 
TLE patients can be carried out using instrumental tools as 
described in "Videofluoroscopic swallow study ", "Fiberop-
tic endoscopic evaluation of swallowing", and Manometry" 
sections. Swallowing impairment should also be evaluated 
from the patients’ perspective using self-report OD ques-
tionnaires. The Swallowing Outcome After Laryngectomy 
questionnaire (SOAL) has been validated specifically for 
patients without a larynx [432, 433]. Such questionnaires 
may be a useful way of monitoring swallowing and sign-
posting the clinician toward the need for further diagnostic 
swallowing assessments. A recently published systematic 
review suggests that the most frequently identified functional 
and/or structural alterations causing OD are weakness of 
the pharyngeal constrictor muscles, increased resistance to 
the passage of a bolus, pharyngoesophageal strictures, and 
pseudodiverticulum formation [434]. It remains unclear 
which pharyngeal closure technique is the best for swallow-
ing [434]. In this systematic review, it was not possible to 
stratify swallowing outcomes per surgical technique due to 
the great variation in the techniques used, for example, TLE 
with primary closure or TLE with partial pharyngectomy 
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and flap reconstruction, total pharyngolaryngectomy with 
different flap reconstructions, gastric pull-up, TLE with or 
without myotomy, etc. (Neo)adjuvant (C)RT had a nega-
tive impact on swallowing although a detailed description of 
these non-surgical techniques was missing in the majority of 
the studies [435–440]. The absence of guidelines for swal-
lowing assessment in TLE patients and the lack of validated 
measurements for this population might explain the great 
diversity of assessment tools that were applied. The body 
of literature on treatment effects of OD after TLE remains 
poor and there is no consensus on the diagnosis and treat-
ment of OD for this population [434]. Some studies showed 
preliminary promising results of botulinum toxin injections, 
endoscopic dilatations, and TOLS [441–448]. However, sig-
nificant treatment effects or trends of these techniques were 
not found. There is a need for well-designed trials using vali-
dated multidimensional swallowing assessment protocols to 
evaluate OD following TLE and to investigate the clinical 
applicability and effects of treatment techniques.
Ethical issues, informed consent, 
and the right to refuse oropharyngeal 
dysphagia treatment
Beneficence, non-maleficence, justice, and autonomy are 
interdependent principles that govern present day clinical 
ethics in most countries [449]. Health professionals apply 
these basic principles in daily care when confronted with 
conflicts of values. The principles by themselves are insuf-
ficient but constitute a framework that helps us to use a 
rational method in reaching decisions. More often than not, 
resolution of ethical conflicts will occur after an interpro-
fessional discussion involving the patient, next of kin, and 
legal representatives or designated persons with power of 
attorney. In the context of OD treatment, health profession-
als will face two types of situations, each with its potential 
ethical conflicts. In the acute situation, the clinical problem, 
its complexity and prognosis will be the primary drivers 
when considering an intervention such as artificial nutrition 
and hydration (ANH) typically of short duration [450]. In 
the context of advanced or terminal illness, patient comfort, 
palliation, and non-maleficence will more strongly influence 
clinical decision-making. Proportionality of the intervention, 
inconvenience and discomfort for the patient, patient prefer-
ence, and the existence of advanced directives will influence 
the outcome. In this situation, ethical conflicts may occur 
and an extensive body of literature on this topic already 
exists as indicated by Druml and colleagues [451]. Given 
nutrition’s vital nature, even proposals for simple interven-
tions to treat OD might be met with moral objections from 
a patient, influenced by cultural or religious factors. The 
abstention of ANH can elicit intense discussions between 
patients, but even more so between families and medical 
teams. Starting abstention and stopping ANH are decisions 
with an important ethical dimension. The Catholic Church 
has agreed that the abstention of ANH is not defined as 
euthanasia, and has recognized that in some circumstances, 
its medical futility can be taken into account [452]. Within 
the Protestant Church many divergent opinions on the sub-
ject exist. The Jewish religion distinguishes between active 
and passive proceedings and might permit the withholding 
of ANH but forbids its withdrawing. For conservative and 
orthodox Jews nutrition is a basic need and not a treatment. 
The Islam religion considers food and hydration as basic 
needs too and not as medical treatment but with patient or 
proxy consent, it can be withdrawn or withheld [451]. It is 
now commonly accepted that ANH is a medical interven-
tion, with all consequences involved and therefore also needs 
informed consent. In the past, health professionals would 
intervene with whatever treatment they considered best for 
the patient. Fortunately, present daycare takes into perspec-
tive the personal preferences of the patient. Therefore, health 
professionals must obtain the patient’s (or the patient’s legal 
representative’s) free and informed consent on OD treatment 
before it commences. Only in emergencies, in non-commu-
nicative patients, and in the absence of representation by 
next of kin should the medical team make decisions in the 
best interests of the patient. Admittedly, physicians some-
times face conflicts of interest when a patient’s or family’s 
decision does not seem to align with the current guidelines 
or evidence-based medicine. This situation can occur when 
cultural, religious or even superstition influences the deci-
sion. The rising problem is that of language barriers and 
hospitals should be prepared to have interpreters on hand 
to help physicians and MDT members communicate with 
patients and relatives in many different languages. Pictorial 
aids could facilitate obtaining consent in children or illiterate 
patients. Experienced SLPs play a role in facilitating com-
munication and should be involved at this point. Obtaining 
informed consent means that the health professionals must 
have clearly informed the patient about the characteristics 
of the intended intervention. Not only how information is 
presented is important in influencing decision-making, but 
also the time needed by the patient to reflect on choices. 
When medical conditions permit, such as in elective surgery, 
the information should be presented as early as possible. The 
future need for TF depends on the extent of the disease, type 
of HNC treatment, and wishes of the individual patient as 
described in "Treatment of cancer cachexia" section. The 
information that should be offered relates to the following 
aspects of the intervention: its purpose, nature, degree of 
urgency, duration, frequency, contra-indications, side effects, 
relevant risks, necessary aftercare, financial consequences, 
possible consequences of a refusal to consent, and the pos-
sible alternatives. In the majority of the European countries 
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a legal cascade of representatives, usually a spouse or next 
of kin, are able to make the final decision in the absence of 
advance directives. More and more people now have writ-
ten “advance directives”, in which they specify the type 
of medical care they would want to receive in a particular 
condition and certainly when he or she would no longer be 
able, due to incapacity, to make such decisions, and stipulate 
who should make those decisions for them. In this “living 
will” people can be granted a durable power of attorney. 
Health professionals should realize that OD is not merely 
the impossibility to ingest food through the mouth to the 
stomach. Eating is not merely the oral ingestion of food, 
followed by several physiological processes that result in 
the production of vital energy. Due to its existential nature, 
being unable to eat or drink has a profound impact on the 
patient (see "Psychosocial impact" section). Therefore, OD 
is accompanied by a significant loss of HRQOL. Caregivers 
often feel morally obliged to start TF, because failing to do 
so would be ‘starving’ the patient. This train of thought is 
understandable, however, sometimes the patient benefit of 
TF is not always clear and the health professional should 
review the benefit in the short, middle, and long term, as 
well as possible complications, the current HRQOL, and 
how it can be improved by TF. A myth that should be dis-
pelled is that the patient who does not want TF is not a can-
didate for swallowing intervention. Even in case of refusal of 
TF, swallowing evaluation and intervention should identify 
strategies to promote the safest means of oral intake.
Head and neck cancer patient perspective
People treated for HNC are usually given information about 
how eating and drinking may be affected, but it is difficult 
for health professionals to adequately convey the reality 
of what it feels like to be a “patient with OD”. Recently, 
Checklin and colleagues published a study on HNC patients’ 
perspectives on OD care experience [453]. They emphasize 
that patients’ perspectives are valuable to increase insight 
into how patients experience their ‘rehabilitative journey’. 
Swallowing is something that we take for granted as human 
beings until it is impaired through illness. The subsequent 
impact is not only on our ability to obtain nutrition, but 
also on socializing, relationships, confidence, and attitude 
to “beat cancer”. Importantly, “survivorship is not survi-
vorship without QOL”. Patient support groups have been 
defined in the literature as “a group of people with com-
mon experiences and concerns who provide emotional and 
moral support for one another,” and may also have a role in 
patient education, improving public awareness, and fundrais-
ing [454]. As a primary function, a support group is a forum 
where newly diagnosed patients, or indeed patients at any 
stage along their journey may seek the help and support of 
someone with the shared experience. This extends to fami-
lies and caregivers who should also form part of this sup-
port network. It is important to recognize that support is 
not unidirectional, and that “veteran” members of a support 
group also benefit from the process. Support groups may 
meet face-to-face, via telephone support lines or have online 
forums, all options showing a positive impact on QOL for 
patients who are involved and engaged in giving and receiv-
ing support [455, 456]. Health professionals should be famil-
iar with the support groups within their local geographic 
area as well as the most suitable online forums. All patients 
with HNC should be offered the opportunity and provided 
with details to contact a support group at the time of diagno-
sis. Depending on individual hospital practice, many support 
groups offer for one of their members to meet with patients 
prior to treatment, a model often used prior to TLE but 
potentially useful for other types of surgery too. The Swal-
lows Head & Neck Cancer Charity (https ://www.thesw allow 
s.org.uk) is one example that offers support and information 
to both patients and caregivers in many forms; including a 
24/7 telephone support line, regular face-to-face monthly 
meeting groups, and an online social media presence pro-
viding topical information relevant to HNC patients. The 
Swallows Charity aims to function as an “umbrella” organi-
zation helping to set up local groups throughout the UK 
and Europe. Thus far, the Charity has eight support groups 
based around England and Ireland. The Charity is looking to 
expand its groups in Spain, Italy, and across Europe during 
2020. The Charity Patient/Carers Book is in its 2nd edition 
and distributed in the UK [457] and Australia [458] and its 
1st edition was launched in Spain [459]. What is important 
is that health professionals are able to signpost patients to 
these options. Collaboration between health professionals 
and patient support organizations facilitates the best care 
and optimal QOL for patients.
Conclusion and topics for future research 
on oropharyngeal dysphagia in head 
and neck cancer
This European White Paper summarizes current evidence-
based literature on OD in HNC and provides recommenda-
tions to support patients and health professionals. Experts 
from the ESSD, the CEORL-HNS, the EHNS, the UEP, and 
the ELS described the state of the art of various diagnostic 
examinations and treatments for OD or OD-related issues 
in HNC. The body of literature and its level of evidence on 
diagnostics and treatment remains poor. For some sections 
of this paper, it was very difficult to come up with a recom-
mendation based on scientific evidence. Therefore, in these 
sections we provide expert opinion to help health profession-
als, caregivers, and patients with multiple challenges due 
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to OD in HNC. Despite the fact that the scientific evidence 
is very limited, it remains challenging to obtain research 
funding in the European Union for studies on OD in HNC. 
Possible reasons are that there is increased competition from 
subjects or conditions with a much higher prevalence than 
HNC, for example, stroke. Research grants also tend to focus 
more on the treatment of cancer itself than on the functional 
impairments or consequences of HNC or its treatment. Yet, 
it is important to note that survival for this population has 
not increased spectacularly in recent decades and approxi-
mately 50% of the HNC patients in the long term die as a 
result of the disease. The question, therefore, arises as to 
whether grant funding agencies should pay more attention 
to HRQOL in the context of OD in HNC.
We anticipate an increase in the prevalence of OD due 
to HNC in the near future. Amongst other factors, further 
aging of our European population (including HNC patients) 
and an increase in the prevalence of HPV-related cancer, 
although the HPV vaccination was introduced in various 
countries, will contribute to this increase in HNC-related 
OD prevalence. We conclude with a call for further imple-
mentation of OD screening in HNC patients and emphasize 
that the need for scientific research on OD treatment remains 
a key challenge for European professional associations and 
policy makers.
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